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Resumo 
 
 
O disfarce do sabor de princípios farmacêuticos ativos é crítico no desenvolvimento de formas de 
dosagem orais sólidas, especialmente para populações pediátricas, mais sensíveis ao gosto dos 
medicamentos. Assim, é essencial melhorar as metodologias existentes e desenvolver novas 
abordagens para avaliação da eficácia do disfarce do sabor. 
Este trabalho focou-se na produção de formulações de sabor mascarado dum fármaco modelo amargo 
e um excipiente apropriado, utilizando diferentes processos de co-precipitação: Reactor Agitado, 
tecnologia AFA (Acústica Focada e Adaptável) e Microfluidização, para comparação no que diz respeito 
às propriedades de disfarce de sabor. Assim, realizou-se um desenho de experiências para estudar o 
efeito de diferentes variáveis de formulação (percentagem de droga, concentração de sólidos na 
alimentação e rácio solvente/antisolvente) nos atributos críticos da qualidade (estado sólido da droga, 
morfologia e tamanho de partícula e dissolução). A eficiência de encapsulação foi seguidamente 
determinada utilizando diferentes métodos de dissolução e também técnicas de caracterização 
superficial (Microscópio Electrónico de Varrimento – Espectroscopia de Energia Dispersiva de Raios-X 
(SEM-EDS) e Espectroscopia de Fotoelectrão de Raios-X (XPS)).  
O sabor das formulações foi mascarado por qualquer um dos processos de co-precipitação utilizados. 
Uma das formulações produzida pela tecnologia de Microfluidização, foi a melhor atendendo à 
eficiência de encapsulação, apresentando menor libertação de droga no fluído salivar simulado nos 
primeiros 5 minutos e melhor eficiência de encapsulação estimada por XPS. Tal, pode dever-se à 
elevada taxa de mistura fornecida pela tecnologia de Microfluidização. Além disso, os resultados dos 
estudos de dissolução com alteração de pH de certas formulações e do produto comercial (comprimido 
revestido) revelaram perfis de dissolução idênticos, indicando que a solubilidade da droga no estômago 
e intestino superior parece não ter sido influenciada pelos processos utilizados. Relativamente às 
técnicas utilizadas para avaliação do disfarce do sabor, a análise EDS apresentou algumas limitações 
enquanto o XPS deu resultados que corroboraram com os dos estudos de dissolução.  
 
 
 
 
 
Termos-chave: encobrimento de sabor, eficiência de encapsulação, processos de co-precipitação, 
dissolução, técnicas de caracterização de superfície  
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Abstract 
 
 
 
Taste masking of Active Pharmaceutical Ingredients (APIs) is critical in the development of solid oral 
dosage forms, since it is related to patient compliance, especially for pediatric populations. Therefore, it 
is essential to improve the existing methodologies and to develop new approaches that allow 
assessment of taste-masking efficacy. 
The current work focused on the production of taste-masked formulations of a bitter model drug 
substance and an appropriate excipient, using different co-precipitation processes: Stirred Reactor, 
Adaptive Focused Acoustics (AFA) technology and Microfluidization, for benchmarking purposes 
regarding taste masking properties. Thus, an experimental design of experiments was conducted to 
study the effect of different formulation variables (drug loading, feed solids concentration and 
solvent/antisolvent volume ratio) in the critical quality attributes of the spray-dried co-precipitated 
powders (drug’s solid state, morphology and particle size and dissolution performance). The 
encapsulation efficiency (EE) was then evaluated by using different dissolution methods and also 
surface characterization techniques (Scanning Electron Microscopy – Energy Dispersive X-ray 
Spectroscopy (SEM-EDS) and X-ray Photoelectron Spectroscopy (XPS)).  
Formulations were taste masked using any of the processes disclosed in this work. One of the 
formulations produced by Microfluidization technology, was the best regarding encapsulation efficiency, 
presenting a lower drug release in simulated salivary fluid within the first 5 minutes and the best 
encapsulation efficiency estimated by means of XPS. This can be explained by a high shear rate mixture 
provided by Microfluidization technology. Moreover, the pH shifts dissolution results for specific 
formulations and a commercial product (coated tablet) revealed similar dissolution profiles, meaning 
that the solubility of the drug substance (in the stomach and the upper intestine) seems not to be 
impacted by the processes used. According with the taste masking assessment techniques, EDS 
analysis presented some limitations and, in this case, it was proved not to be adequate, contrary to XPS 
which results corroborated the dissolution ones.  
 
 
 
 
 
 
 
Keywords: taste masking, encapsulation efficiency, co-precipitation processes, dissolution, surface 
characterization techniques 
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1. Introduction 
 
1.1. Taste 
 
Taste is defined as the ability of certain cells called taste buds, present all over the surface of the tongue, 
to percept the flavor of different substances such as food, poisons, minerals and medications (Chirag et 
al., 2013; Vummaneni and Nagpal, 2012). The mechanism of taste transduction can be conducted by 
two different forms: the first, based on electrical changes within taste cells, promoted by the diffusion of 
given ions in the ion channels and the other, involves a complex process of the activation of G-protein-
coupled receptors (GPCRs) on the apical surface of taste cells, where the tastants bind (Purves et al., 
2001). 
According to the chemical structure of the compound, the type of the ions produced in saliva, solubility 
and the degree of ionization, the sensation interpreted by the brain is different (Shet and Vaidya, 2013). 
For that reason, there are four primary sensations of taste (sour, salty, sweet and bitter) and a fifth called 
umami.  
The localization of the bitter taste buds is toward the back of the tongue. The bitter taste sensation is 
caused by almost all organic substances, in particular very long chains ones and alkaloids (for example, 
quinine, caffeine, strychnine and nicotine). Also, high molecular weight salts may have a bitter taste 
(Guyton, 1977; Shet and Vaidya, 2013). 
 
1.2. Relevance of Taste Masking 
 
Taste masking has been gaining importance since the majority of APIs found on oral dosage forms 
present a bitter taste. Examples include macrolide antibiotics, non-steroidal inflammatory and penicillins 
(Karaman et al. 2014; Maniruzzaman et al. 2014; Karaman et al., 2015). 
The need to improve palatability during the development of oral dosage forms has been rising in the last 
few years. It has become a focus of attention and study, due to patient compliance, especially for people 
that suffer from chronic diseases, generally geriatric population (Bhalekar et al., 2014; Pawar and Joshi, 
2014) and in particular, for children, since they are more sensitive to the bitter taste, presenting a higher 
number of taste buds than in adults (Pandey et al. 2010).  
In fact, the American Academy of Pediatrics estimates that the average compliance in children was 
approximately 50% in the beginning of the 21st century, in other words 50 in 100 children failed when it 
came to take the medication (Winnick et al., 2005).  
Thus, for medication to be effective it is necessary to be taken appropriately (Matsui, 1997). If this is not 
the case, it can result in the persistence of the patient’s disease symptoms, requiring the use of 
additional drugs, the need for additional medical appointments and even hospitalizations, which 
increase healthcare costs, both for the patient and the state. The development of drug-resistant 
organisms is also a huge concern related to this issue (Suthar and Patel, 2010). 
Therefore, taste masking is essential allowing a reduction on the perception of the bitter taste. In general, 
taste making can be achieved by two different modes: reduce the solubility of the drug in the pH of saliva 
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or change the nature and affinity of the drug, which will interact with the taste bud receptor (Sagar et al., 
2012; Tripathi et al., 2011). 
 
1.3. Overview of Taste Masking Approaches  
 
In the last decades, innumerous approaches were proposed for taste masking purposes, such as 
addition of sweeteners, coating, solid dispersions, inclusion complexes, granulation, ion exchange 
resins and microencapsulation (Vummaneni and Nagpal, 2012).  
In regards to the evolution of the number of published patents, related with taste masking technologies 
along the years, which is illustrated in figure 1.1, it is possible to conclude that there is a tendency, since 
the beginning of the millennium, for the stabilization of the number of published patents related with the 
addition of sweetener agents. Beyond that, coating technology shows the biggest development in terms 
of studies with published patents in the last decades. Other technologies, such as microencapsulation 
and granulation, have also shown merit resulting in new published patents. 
 
 
 
 
 
 
 
 
Figure 1.1 Evolution of the number of published patents related to taste masking technologies between 1997 to 
2007 (adapted from Ayenew et al. 2009). 
 
To select the most appropriate approach, it is necessary to take into consideration factors like: 
 dose of API - usually, with high doses the coating approach is used while with small doses, 
sweeteners and flavoring agents are added to the formulation (P. Kumar, 2015); 
 intensity of the drug’s bitter taste - for extremely bitter drugs, the use of simple techniques, like 
the addition of sweeteners, may be insufficient by itself to achieve taste masking, therefore 
complementary techniques like coating and microencapsulation are used to improve the 
efficiency of taste masking (Chirag et al. 2013; Karaman 2012); 
 type of dosage form; 
 drug solubility; 
 ionic characteristic of drug; 
 drug particle shape and size distribution - if the final particles have core materials with irregular 
shapes and small particle size (PS), it may result on poor efficiency of taste masking (Chirag et 
al., 2013). 
In this thesis, a new microencapsulation approach was used for taste masking purposes of a bitter taste 
antibiotic selected as model compound. By coating the particles, a physical barrier is created between 
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the drug and the taste buds receptors, resulting on the reduction on drug solubility and consequent taste 
improvement (Sourabh et al., 2012). In table 1.1 it is presented the taste masking state of the art, using 
microencapsulation as the main approach. 
 
Table 1.1 List of several drugs that were taste masked through microencapsulation process. 
Drug Polymer Aim of the study 
Techniques 
used 
References 
beclamide 
Gelatin, anhydrous 
sodium sulfate 
Mask the bitter taste 
Simple 
coacervation 
(Ozer and 
Hincal, 1990) 
cefuroxime 
axetil 
CAT,BP MCP-55 
UPMCP 50 
Mask the bitter taste and 
assure its release in the 
intestinal cavity 
Solvent 
evaporation 
and solvent 
extraction 
(Cuña et al., 
1997) 
diclofenac 
sodium 
Ethyl cellulose 
Mask the bitter taste, 
without affecting the drug 
release rate 
Precipitation 
(Al-Omran et 
al., 2002) 
flucloxacilin 17 % Ethyl Cellulose 
Assure the availability for 
taste abatement of the 
drug from the tablet as the 
raw unprocessed antibiotic 
n.s. 
(Maccari et al. 
1980) 
ibuprofen 
Methacylic acid 
copolymer 
To obtain chewable taste 
masked tablet with release 
characteristics. 
Fluid Bed 
Coating 
(Shen, 1991) 
indeloxazine 
Hydrogenated oil and 
surfactant 
Assure the taste masking 
of the drug and the 
bioavailability by heat 
treatment. 
Fluidized bed 
using the side-
spray method 
(Sugao et al., 
1998) 
 
1.4. Motivations and Objectives 
 
The microencapsulation of the particles can be achieved using different techniques, namely spray drying 
(SD), spray congealing (SC), fluid bed coating, coacervation phase separation, among others. The focus 
of the current work was to develop and study alternative processes for the microencapsulation of active 
ingredients and enhance taste masking properties. 
Thus, this thesis discloses alternative processes that are based on co-precipitation principles, in 
particular liquid antisolvent precipitation, with the main goal of producing taste masked formulations of 
a model drug. 
Several goals were defined for this thesis: 
 
I. To investigate the conventional antisolvent precipitation process in a stirred batch reactor, 
producing taste masked formulations of the model drug, according to the design of experiments 
(DoE), and to study the impact of the formulation variables on the critical quality attributes 
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(CQAs) (solid state, particle size and morphology and in vitro performance), as well as taste 
masking properties; 
 
II. To develop a novel antisolvent precipitation process based on microfluidization, using a new 
setup PureNanoTM, producing taste masked formulations of a model drug and studying the 
impact of the aforementioned formulation variables in taste masking properties and CQAs; 
 
III. To study through an innovative technology called Adaptive Focused AcousticsTM (AFA) system 
based on ultrasound treatment, developed by Covaris® (company that provides technologies 
that allow to improve sample preparation and novel drug formulations), the same formulations 
produced by PureNano and stirred batch reactor approaches; 
 
IV. To benchmark the different technologies used in this thesis, by comparing and studying the 
impact that the use of each technology has in the critical quality attributes and more important, 
in taste masking properties; 
 
V. To develop and apply analytical characterization techniques to assess the efficiency of 
encapsulation of the produced formulations. 
 
1.5. Thesis Layout 
 
In Chapter 2, a literature review is given, presenting the main work related with existing taste masking 
technologies, with special focus on the co-precipitation method. 
Chapter 3 presents a selection of current literature on the existing taste masking assessment 
technologies, with particular reference to in vitro dissolution studies and also characterization surface 
techniques, since those will be the methods of particular relevance in this project. 
Chapter 4 describes the materials and methods applied in this research, as well as the methodology or 
protocol followed for each laboratory experiment or analytical characterization. 
The results and discussion of the experimental work developed in the laboratory and analytical 
characterization of the powders produced are presented in Chapter 5, with the main purpose of 
benchmarking co-precipitation technologies regarding the taste masking properties. This chapter is 
divided in six subchapters: the first four are related with general aspects of analytical characterization 
of the spray-dried co-precipitated powders - morphology, particle size, drug’s solid state and also drug 
content in the formulations -, while the last two subchapters are related to the determination of 
encapsulation efficiency and taste masking properties – in vitro dissolution studies, determination of 
encapsulation efficiency using SEM-EDS (Scanning Electron Microscopy-Energy Dispersive 
Spectroscopy) and XPS (X-Ray Photoelectron Spectroscopy) analysis. 
Chapter 6 presents the general conclusions obtained in this work and also provides some 
recommendations for further research and work.   
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2. Overview of Taste Masking Technologies 
 
2.1. Spray Drying (SD) 
 
SD emerged during World War II with the necessity to reduce the transport weight of foods, e.g. the 
production of powder milk, and other materials (Patel et al. 2009). It is a powerful technique for particle 
engineering used  in many applications in the pharmaceutical industry, and among the different taste 
masking technologies is one of the most simple and viable approaches (Dobry et al., 2009; Kaushik and 
Dureja, 2015). 
In SD, a stream - solution, suspension or emulsion - is fed, at controlled rate flow, to an atomizer, located 
inside the chamber, concurrently or counter currently with a hot drying gas. The atomizer will transform 
the solution into very fine droplets, and the hot drying gas is responsible for the drying of the particles. 
These are then collected and separated from the hot drying gas, through a cyclone, usually followed by 
a bag-filter, that will collect the fine particles existing in the system (Dobry et al. 2009; Gil et al. 2010).   
Spray dryers can operate in different configurations. Generally, laboratory SD’s operate in an open cycle 
mode, where drying gas passes to the chamber and then is exhausted to the appropriate waste stream 
(BETE Fog Nozzle, 2005; Dobry et al., 2009). Many large pilot-scale and production-scale SD’s operate 
in a closed-loop mode, characterized by a gas recycle unit. The hot gas passes through a condenser to 
remove the residual solvent and then, is reheated in a heat exchanger, to obtain the initial operational 
conditions, being reinserted in the drying chamber (Dobry et al. 2009; Gil et al. 2010), as illustrated in 
figure 2.1. 
 
Figure 2.1 Closed cycle Spray Drying equipment configuration, at green is represented the gas recycle unit 
(adapted from Dobry et al. 2009). 
 
The atomization is an essential step, since it controls the droplets size and consequently the particle 
size. There are several types of nozzles used for atomization and the most commonly used are rotary, 
pressure, two-fluids and ultrasonic nozzles (Gil et al. 2010; Kaushik and Dureja 2015). The selection of 
the suitable type of nozzle has to take into consideration the intended morphology and particle size (e.g., 
a narrow particle size distribution (PSD) is obtained using a pressure nozzle instead of two fluid nozzle), 
as well as the viscosity of the liquid stream (e.g., two fluid nozzle has a lower sensitivity to viscosity 
when compared to pressure nozzle).  
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Sollohub et al. (2011) used SD to obtain microparticles of roxithromycin with high taste masking 
efficiency. These authors concluded, through an electronic tongue study, that in water the taste masking 
effect remained at least several dozen hours.  
Bora et al. (2008) studied the use of three different polymers (Chitosan, Methocel E15 LV and Eudragit 
E100) for the formation of taste-masked microspheres of intensely bitter drug ondansetron hydrochloride 
(OSH) by SD. The authors concluded that in Methocel microspheres the taste masking was absent for 
all the drug-polymer ratios. The Chitosan microspheres showed taste masking at 1:1 drug-polymer ratio, 
whereas Eudragit microspheres displayed taste masking at 1:2 drug-polymer ratio. Dissolution studies 
reveal, for Eudragit microspheres, 97 % of drug release within 15 min, while for Chitosan microspheres 
was verified a drug release of 40 %. Thus, the selection of the suitable polymer and also the proportion 
between polymer and drug is very important since it can affect the properties of the final product, namely 
the dissolution of the drug and taste masking properties. 
Lukas et al. (1997) developed paracetamol taste masked formulation by SD method using ethyl cellulose 
as the coating material. According to this study, the use of coating material with less than 23 % of the 
total weight of the formulation, provides taste masking characteristics. The authors proved that the 
coated paracetamol composition, prepared in a first phase as a powder and then transformed into 
tablets, exhibits immediate release properties, maintaining the taste masking properties.  
 
2.2. Spray Congealing (SC) 
 
Another technique used for microencapsulation, is spray congealing or spray chilling. This technique 
relies on the same principle as SD, however the API is dissolved (or suspended) in a melted excipient 
(typically, matrix material), forming a molten mixture that is atomized into a cooling air, where the molten 
droplets are congealed leading to the particle formation (Mackaplow et al. 2006). Matos and Duarte 
(2016) and Qiyun (2008) consider that the transformation of molten droplets from liquid to solid occurs 
with the removal of energy from the droplets.  
Yajima et al. (1996) assessed the palatability and taste of clarithromycin (CAM) formulation through SC 
technique. Results were significantly better when compared with conventional coated granules. 
Moreover, the in vitro dissolution studies showed that in a buffer solution at pH=6.5, the amount of CAM 
released was less than the threshold concentration of the bitter taste (14 mg/L). 
Maschke et al. (2007) reported that the application of SC technique for the preparation of insulin-loaded 
lipid microparticles led to a good EE, since the microparticles did not show a burst release in the 
dissolution test. Thus, an efficient encapsulation can inhibit the escape of API from microparticles, 
enabling a lower perception of the bitter taste. 
Similarly, Cordeiro et al. (2014) analyzed the taste masking efficiency of a model drug (quinine sulphate) 
produced through SC and Hot Melt Extrusion (HME) techniques by SEM-EDS and fluorescence 
microscopy. By SEM-EDS, the sulphur element peaks were not detected (characteristic from API 
molecule) in the surface of the particles produced by SC, while these peaks were detected in the surface 
of particles produced by HME. Regarding the fluorescence microscopy trials, the extruded material 
revealed a higher intensity of fluorescence when compared with spray congealed particles. Therefore, 
in terms of taste masking better results were obtained with the SC technique then with HME. 
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2.3. Hot Melt Extrusion (HME) 
 
Joseph Brama established the HME process in the end of the eighteenth century. It can be applied to a 
large range of pharmaceutical dosage forms such as capsules, tablets, films and implants for drug 
delivery via oral, transdermal and trans mucosal (R.V. Tiwari et al. 2016). For that reason, HME is a 
good alternative to other conventional methods, such as SD (Maniruzzaman et al. 2012).  
HME allows to melt blends of polymer, excipients and API, forcing the material to pass by an hole, 
compressing it and converting it into a uniform shape product (Maniruzzaman et al. 2012; Particle 
Sciences Inc. 2011). The process requires a premixing step, where the API, polymer and excipients are 
blended and then inserted into the rotating screw by an hopper (Patel et al. 2013). The extruder is mainly 
divided into three zones: feeding, melting or compression, and metering, as shown in figure 2.2. 
 
Figure 2.2 Schematic representation of mainly sections along a single screw extruder (adapted from (Patel et al. 
2013)). 
 
The process requires downstream auxiliary equipment to finish, shape and analyze the extruded 
material, being necessary to cool, cut and/or collect the finished product, and obtain it in the desired 
shaped (Kolter et al., 2012).  
Pimparade et al. (2015) developed taste masked caffeine citrate formulations using HME. They 
performed an in vitro study, which revealed an insignificant amount of drug release in the salivary 
medium, while in 0.1 N Hydrochloride Acid (HCl) a drug release over 80 % within the first 30 min was 
obtained. Likewise, Petereit et al. (2014) produced taste masked verapamil HCl granules via HME using 
Eudragit L100/L100-55. They identified as responsible for taste masking, the strong hydrogen bonding 
interaction with the functional group of the API-polymer mixture. The efficiency of taste masking 
formulations with different drug loads was evaluated, concluding that for drug loadings about 30-50% a 
neutral taste was verified. However, when the drug load was increased to 70% a slightly bitter taste 
perceived. In addition, taste masking efficiency can be improved by increasing the temperature and the 
screw rotation speeds. 
 
2.4. Co-precipitation 
 
According to Simonelli et al. (1969) the co-precipitation arises in pharmaceutical industry to produce 
amorphous solid dispersions (ASD’s), based on the simultaneous precipitation of drug and polymer by 
changing the solubility conditions. 
It occurs when two components, simultaneously, exceed their solubility, resulting in the incorporation of 
the minor component in the matrix of the major one (Shah et al. 2014). The co-precipitation became 
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known both for the production of compounds with small particle size and the improvement of the final 
properties of challenging crystalline APIs (I. Duarte, 2016; Pouretedal, 2014; Thorat and Dalvi, 2011). 
Nowadays, this technology has been emerging to improve the drug solubility (I. Duarte, 2016) and also 
for taste masking applications. In this way, Sharma et al. (2012) compared the results obtained for 
several sumatriptan succinate formulations produced by different taste masking technologies, and 
concluded that the precipitation method was one of the best techniques for this particular drug. All the 
volunteers that made part of the human panel considered the formulation as being completely taste 
masked. In the same way, Limmatvapirat et al. (2012) showed that the taste masking of 
dextromethorphan (DEX) can be easily accomplished by the co-precipitation technique, using a shellac 
(SHL) based matrix. The major evidence was an in-vitro study in artificial saliva at DEX-SHL weight 
ratios of 5:10 or less, that revealed a drug release lesser than 1 %. 
 
2.4.1. Phase Equilibrium and General Considerations 
 
The solubility is defined as the capacity of a solute to dissolve in a solvent originating a homogeneous 
solution, i.e., the maximum concentration of solute that can exist in a certain volume of solvent in 
equilibrium with the solid form of the solute precipitated. The equilibrium of solubility is dynamic, and in 
certain conditions the concentration of solute may exceed the solubility value to originate a suspension 
(Savjani et al., 2012).  
The equilibrium phase diagram of solubility showed in figure 2.3, is an important tool to understand the 
causes of the precipitation phenomena, and also which is the more adequate process for the production 
of a given drug substance.  
 
Figure 2.3 Phase equilibrium diagram with the different zones, where it is represented the trajectory to the 
cooling precipitation (red line), evaporative precipitation (blue line) and antisolvent precipitation or drowning out 
(green line) adapted from (Cogoni, 2012; Smith, 2005). 
 
There are three distinct zones figuring out in the diagram: undersaturated region - crystals will dissolve, 
it is also called stable zone -, metastable region - supersaturated region, in which crystals grow through 
heterogeneous nucleation – and, supersaturated region – in which occurs spontaneous nucleation 
and crystal growth (Cogoni, 2012; Paiva Lacerda, 2013). 
According to Mansour et al. (2013), the process of precipitation involves the creation of supersaturation, 
that induce nucleation and simultaneously growth by coagulation or condensation. However, the 
agglomeration can become more evident if the growth occurs uncontrolled. As known and as highlighted 
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by Panagiotou and Fisher (2011), in order to generate solids from a liquid phase, the thermodynamics 
aspects are important. Therefore, firstly it is necessary to change the thermodynamic state of the 
solution to reduce the solubility of the compound, by temperature, pH and concentration changes or 
altering the solubility coefficients (Agrawal, 2010). 
In the unstable region, it is not necessary to have heterogeneous nucleation sites to initiate the formation 
of the solid phase. In this zone, as the supersaturated liquid isn’t stable neither is in equilibrium, take 
place a spontaneous homogeneous nucleation and rapid growth of the solids. Panagiotou and Fisher 
(2008) look at this zone as the desired initial operational region, since leads to the creation of a large 
number of nucleation sites, minimizing the ultimate size of the individual particles and making possible 
the control of particle’s morphology.  
Thorat and Dalvi (2011) realized that the high and rapid supersaturation is the main driving force of the 
process and Cogoni (2012) has proposed a way to calculate it through the change in chemical potential 
between standing and equilibrium states. 
Nucleation is a result of the molecules combination of a particular element, in a process called molecular 
assembly. Nucleation may be heterogeneous, as previously said, or homogeneous, depending on 
whether it uses foreign substances or not, respectively. After the process of nucleation, the crystal 
growth dominates, allowing to obtain a crystal form with defined size and shape (Sriamornsak and 
Burapapadh, 2015). 
 
2.4.2. Precipitation Techniques 
 
There are several precipitation methods that have been used in pharmaceutical industry, such as: melt, 
evaporative and cooling precipitation (Sriamornsak and Burapapadh, 2015), supercritical antisolvent 
precipitation (SAS) and antisolvent precipitation (Danish et al., 2013).  
 
2.4.2.1. Cooling Precipitation 
 
This process is based on the fact that temperature affects the solubility of the majority of the compounds 
(Holañ et al., 2015) and is the most widely used technique to create supersaturation (Wey and Karpinski, 
2002).   
This technique is applied when the solubility of a substance decreases significantly with temperature 
(Baliga, 1970). In figure 2.3 a trajectory from a cooling process from point A to point B is illustrated. Point 
A is located in the unsaturated zone; by cooling, the process can be directed towards the metastable 
zone. Then, a specific cooling and controlled profile is designed until the final temperature, which allows 
us to obtain the desirable properties of the crystals (Smith, 2005).   
In this process, the tank is fed with the unsaturated solution that is cooled inside the tank or via an 
external jacket. In order to keep supersaturation practically constant during the cooling period the 
cooling rate should be set (Mersmann 2001).  
Raghavan et al. (2003) prepared a pediatric formulation of taste masked gatifloxacin using a cooling 
precipitation method, resulting in a crystalline co-precipitate of gatifloxacin with a stearic acid and/or 
palmitic acid. They reported the efficiency of taste masking in mouth and in aqueous suspension through 
a full dosage cycle of about fourteen days.  
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Similarly, Bellinghausen et al. (2009) invented a new taste-masked powder, for oral administration with 
the formation of a coated solid, by a cooling precipitation method. The authors proved that, the bitter 
taste of praziquantel with Wax C80 wasn’t perceived, even after a period of 10 minutes after the tablet 
application, into the tongue. In fact, even if the formulation had been chewed for a few minutes, it did 
not release the bitter taste.  
 
2.4.2.2. Evaporative Precipitation 
 
As the name implies, the creation of supersaturation in this method is a result of the solvent evaporation, 
leading to the formation of a solid phase (Lewis et al. 2015).  
This technique can be applied for compounds that have an “inverse” dependence of the solubility with 
temperature (e.g. Na2SO4) or that the solubility depends weakly on temperature (e.g. NaCl) (GEA 
Process Engineering, 2012; Giulietti et al., 2001). The equipment used for this process operates at 
reduced pressure (GEA Process Engineering, 2012) and constant temperature (Wey and Karpinski, 
2002). 
In this process, the tank is fed with an undersaturated solution, which is heated until the boiling point of 
the solution to promote a faster evaporation of the solvent. Once again, in order to keep the 
supersaturation practically constant it is favorable to set the rate of evaporation so that an optimum 
value for crystal size distribution may be obtained (Mersmann, 2001). 
Shishu et al. (2010) developed taste masked ordinazole microspheres by solvent evaporation technique, 
and the taste assessment was done by panelist. All the voluntary humans reported microspheres as 
tasteless, however when microspheres were compressed into Fast Disintegrating Tablets (FDTs) the 
majority of people classified it as a good taste and only one person as tasteless. Thus, the final dosage 
form is a factor to have in account, since it impacts the taste masking properties.  
 
2.4.2.3. Antisolvent Controlled Precipitation (ACP) 
 
The ACP is also known as a bottom up approach, based on the arrangement of atoms, molecules or 
macromolecules, making possible a better control of particle size and a more homogeneous particle 
size distribution (De et al., 2014). The concept of antisolvent controlled precipitation (ACP) is the mix of 
a solution, composed by API and excipient dissolved in a certain solvent, with an antisolvent, in which 
the API must be insoluble. The mix of the solution with the antisolvent is responsible for an increasing 
of supersaturation, leading to the precipitation, as a result of a reduction of drug solubility (Matsumoto 
et al. 2013; Viçosa et al. 2012). In figure 2.4, the process aforementioned explained is shown. 
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Figure 2.4 Schematic representation of a batch antisolvent precipitation process (adapted from (Yu et al., 2005)). 
 
The antisolvent precipitation has been used to produce co-crystals (Wang et al., 2013), single drug  
particles (Dong et al., 2009; Viçosa et al., 2012) and amorphous solid dispersions (Í. Duarte et al., 2015; 
Porfírio et al., 2015; N. Shah et al., 2013). The process can operate at two modes: batch and continuous 
confined flow. In a batch process, the solution with the API and polymer is injected into the vessel by a 
small orifice, promoting the rapid mix of the resulting suspension. The main drawback is the poor mixing 
when compared to the continuous confined geometries, thus the control of the particle size could be 
compromised, conducting to the production of larger size particles (D’Addio and Prud’homme, 2011).  
An alternative is the simultaneously injection of solvent and antisolvent streams into a cavity called 
“confined impinging jet” (CIJ) mixers. There are other geometries like static mixers, Y-mixer and 
“multiple inlet vortex mixers” (MIVM). Thakur et al. (2003) indicated the following as main pros when 
compared to the traditional continuous stirred-tank reactor (CSTR): the small space required, short 
residence times, good mixing at low shear rates, low equipment cost and no power required except 
pumps. However, scale-up may be difficult since there is a tendency to clog easily (Alvarez and 
Myerson, 2010). 
This technique has been employed to produce several drugs, with a specific particle size according to 
the operational conditions, as indicated in table 2.1. Regarding the information collected in the table, the 
most commonly used solvents are ethanol (Kakran et al., 2013; S. Kim et al., 2012) and methanol (H. 
X. Zhang et al., 2009; Z. Zhang et al., 2012). However, in some cases may be required the use of other 
type of solvents like dimethylsulfoxide (DMSO) (Panagiotou et al., 2009) or dimethylacetamide (DMA) 
(Li et al., 2011). Distillated water is typically used as antisolvent (Park and Yeo, 2012; Sriamornsak and 
Burapapadh, 2015; Wang et al., 2013; Yu et al., 2005). The value of stirring speed widely used in the 
studies presented in the table is 1000 rpm. Nevertheless, some authors study higher speed agitations. 
Although the size of the particles depended on a panoply of factors, the stirring speed is clearly 
important. Thus, Yu et al. (2005) studied the effect of agitation speed (200-600 rpm) in the agglomeration 
and particle size and concluded that a lower agitation speed, result in an excessive nucleation and highly 
agglomerated products. Also noted, that when the stirring speed was increased smaller particles were 
produced due to the disruption of the agglomerates. Other authors, namely  Kakran et al. 2013; C. Li et 
al. 2011; Nyvlt and Zacek 1986, reached to similar conclusion. 
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Table 2.1 Previous work done in the production of APIs using ACP process (T-temperature (ºC), S-solvent, SA 
Ratio-solvent/antisolvent ratio, SS - stirring speed (rpm), PS – particle size (𝜇𝑚), n.s.- not specified). 
Drug Aim of the sudy Operational Conditions Ref. 
artemisinin 
Enhanced 
dissolution rates 
T: 10-20 
S: Ethanol 
SA Ratio: 1:10-1:20 
SS: 200-1000 
DC: 5-15 
PS: Diameter-1,5; 
Length-3,8 
(Kakran et al., 
2013) 
atorvastacin 
Prepare ultrafine 
powder 
T: n.s. 
S: Methanol 
SA Ratio: 1:10 
SS: 1000 
DC: 20-80 
PS: 1-3 
(H. X. Zhang et 
al., 2009) 
bicalutamide 
Enhanced 
dissolution rate 
T: 3-30 
S: N,N-dimethyl 
acetamide 
SA Ratio: 1:20 
SS: 1000-15000 
DC: n.s. 
PS: 0,326-0,334 
(C. Li et al., 
2011) 
carbamazepine 
Study the effects 
of the process 
parameters 
T: 25-45 
S: Ethanol 
SA Ratio: n.s. 
SS: n.s. 
DC: 10-40 
PS: 13,9-112,3 
(Park and Yeo, 
2012) 
curcumin 
Improved 
dissolution 
properties 
T:  5-25 
S: Ethanol 
SA Ratio: 1:10-1:20 
SS: 200-1000 
DC: 5-15 
PS: Diameter: 
0,155-0,30; 
Length: 0,920-
1,68 
(Kakran et al., 
2012) 
irbesartan 
Enhanced 
dissolution rate 
T: n.s. 
S: Methanol 
SA Ratio: n.s. 
SS: 2500 
DC: 1 %wt. 
PS: 0,055 
(Z. Zhang et al., 
2012) 
nitrendipine 
Enhanced 
dissolution and 
oral bioavailability 
T: 3 
S: Mixture of PEG 
200 and acetone (1:1) 
SA Ratio: n.s. 
SS: 400 
DC: 30 
PS: 0,2-0,218 
(Xia et al., 
2010) 
norfloxacin 
Produce 
nanosuspensions 
T: n.s. 
S: Dimethylsulfoxide 
SA Ratio: 1:3-1:10 
SS: n.s. 
DC: 5-20 
PS: 0,17-0,35 
(Panagiotou et 
al., 2009) 
quercetin 
Enhanced 
dissolution 
T: n.s. 
S: Ethanol 
SA Ratio: 1:10-1:25 
SS: 300-1000 
DC: 5-15 
PS: 0,17±0,03-
0,56±0,02 
(M. Kakran et 
al. 2012) 
rifaximin 
Taste Masking 
and enhanced 
solubility 
T: <3 
S: Mixture of PEG 
200 and acetone (1:1) 
SA Ratio: 1:10 
SS: 400 
DC: 200 
PS: 0,129 
(Danish et al., 
2013) 
trans-resveratrol 
Enhanced oral 
bioavailability 
T: 5-25 
S: Ethanol 
SA Ratio: n.s. 
SS: 1000 
DC: 60 
PS: 0,232-0,560 
(S. Kim et al., 
2012) 
 
As the previous table shows, the majority of the recent studies performed, using an antisolvent 
precipitation process, had the aim of enhancing dissolution rates, only existing a reference pointing out 
the study of taste masking effects. 
Danish et al. (2013) based on in-vitro studies, suggested that by reducing the particle size of 
formulations of rifaximin, through the preparation of nanosuspensions by antisolvent precipitation, the 
efficiency of taste masking can be improved. 
Kulkarni et al. (2005) developed a taste masked pharmaceutical composition of cefuroxime axetil (an 
extremely bitter taste drug) comprising a pH sensitive polymer through antisolvent precipitation, using 
acetone as solvent and water as antisolvent. According to the authors, X-ray Diffraction (XRD) and 
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Differential Scanning Calorimetry (DSC) data support that the use of higher molecular weight polymers 
is efficient in taste masking. Also, it was shown that even at very low drug polymer ratio there was an 
inhibition of drug’s crystallization in the amorphous matrix. 
Table 2.2 contains a summary of the main advantages and disadvantages of taste masking technologies 
aforementioned. Despite some limitations of the ACP process, the benefits of this technique towards 
other methods are notorious. Firstly, only ACP and SD methods are suitable for processing heat 
sensitive molecules, since they are low temperature processes. Secondly, ACP is also appropriate for 
compounds that are difficult to formulate, called “brick dust” compounds, since they can’t be processed 
by melt-based techniques, as long as they have low solubility in volatile organic solvents and high 
melting points (Sandhu et al. 2014). Thus, they are dissolved, without affecting their chemical stability, 
in polar solvents with high boiling points, such as dimethylformamide (DMF) or DMA, which isn´t possible 
with an SD technique (I. Duarte, 2016). An example of a successful commercial product, recently 
developed through ACP to try to solve this problem, was Zelboraf. The production of this commercial 
product was based in vemurafenib ASD, which is the API for the treatment of melanoma (N. Shah et al., 
2013). 
Finally, a huge advantage of ACP is the fact that the particle’s size and morphology can be controlled 
by adjusting the parameters of the process such as flow rates, agitation speed, temperature, etc. 
However, the properties of the final product depend not only on the operational conditions 
aforementioned (Holañ et al., 2015; Lonare and Patel, 2013) but also on formulation variables, such as 
properties of the drug, polymer, drug load and solvent/antisolvent (SAS) volume ratio (Lonare and Patel, 
2013). As an example, and according to Miller et al., (2007) the intimately mixing of the drug and 
hydrophilic excipients reduce the mean crystal size, resulting in an increased surface area with improved 
wetting properties, that will lead to an enhanced dissolution rate. Regarding the formulation variables, 
Zu et al. (2014) observed that by increasing the SAS volume ratio from 1:2.5 to 1:10 the average particle 
size of taxifolin decreased from 40 nm to 20 nm. This suggests that the amount of ultrafine particles 
generated per unit volume of liquid, was reduced by increasing the SAS volume ratio, i.e. a lower 
population density, that leads to a reduction of the collision and agglomeration phenomena between the 
particles (Thorat and Dalvi, 2011), contributing for a smaller particles formation.  
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Table 2.2 Advantages and limitations of taste masking technologies. 
Methods Advantages Limitations References 
SD 
- Continuous Process (allows change operating conditions without 
interruption); 
- Fast process; 
- Flexible particles sizes; 
- Thermosensitive products can be processed under low 
temperature and pressures due to the short contact time with the 
heat source; 
- Large equipment required; 
- High initial cost of the units; 
- Droplet/particle deposition on the chamber walls; 
- Difficulty in cleaning; 
- Use of solvents; 
- Low throughput; 
- Generally, production of irregular geometry and 
porous surface due to the evaporation solvent. 
(Mujumdar et al., 2010); 
(Oliveira and Petrovick, 
2010); 
(Qiyun, 2008); 
(Oliveira W.P et al. 
2010); 
(K. Kolter et al. 2012) 
SC 
- Free process solvent; 
- Fast cooling process (formation of droplets/particles in few 
seconds); 
- Production of spherical and dense particles suitable for tableting, 
capsule filling or injection; 
- Don’t require post processing, like secondary drying, milling or 
pelletization; 
- Less energy consumption and time when compared with SD. 
- Not suitable for heat labile molecules; 
(Cordeiro et al. 2013); 
(Matos and Duarte, 
2016); 
(Okuro et al. 2013); 
(Duarte et al. 2016) 
HME 
- Fast, simple, economic, continuous process and easy to scale-up; 
- Processing in absence of solvents; 
- Possible to shape the drug-matrix mixture into implants or oral 
dosage forms; 
- Suitable to moisture sensitive actives. 
- Limited number of available polymers; 
-Flow properties of polymers are essential to the 
process; 
- Thermal process (drug/polymer stability); 
-Not suitable for relatively high heat sensitive 
molecules (like proteins, microbial species); 
- High energy input; 
- Downstream process (milling or pelletization of 
extruded). 
(Jagtap et al. 2012); 
(Maniruzzaman et al. 
2014); 
(Dixit AK et al. 2012); 
(Patil et al. 2016); 
(R.V. Tiwari et al. 2016); 
(K. Kolter et al. 2012); 
(M.M. Crowley et al. 
2007) 
ACP 
- Rapid, easy to perform and easily scalable; 
- Adaptable from batch to continuous processing; 
- Low temperature process (suitable for heat-sensitive substances); 
- Particle size and morphology controlled by adjusting the 
parameters (flow rates, temperature, etc.); 
- Not necessary the dissolution of API and excipient in the same 
solvent (the excipient may be dissolved in the antisolvent); 
- Suitable for “brick dust” compounds; 
- Particles with high surface area; 
- Reproducibility; 
- Require less consumption energy than evaporation process. 
- Utilization of solvents; 
- Difficult to remove completely the solvents 
used (leading to physical and chemical 
instabilities of formulation); 
- Difficulty in maintaining the size of the 
particles produced after precipitation (with a 
rapid growth rate that leads to a broad PSD); 
- Not applicable to drugs that are poorly 
soluble in aqueous and nonaqueous media; 
- Tendency for the agglomeration of organic 
compounds as fine particles into amorphous 
structures. 
(Viçosa et al., 2012); 
(Kurup et al. 2016); 
(Lonare and Patel, 2013); 
(Krishna et al. 2015); 
(Sandhu et al. 2014); 
(Peltonen et al. 2016); 
(Savjani et al., 2012); 
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3. Overview of Taste Masking Assessment Technologies 
 
In case of APIs incorporated in solid oral dosage forms, it is extremely important to mask their bitter 
taste, since the drug can be released in the oral cavity (Pein et al. 2014). 
The formulations can be evaluated in regard to taste masking using in vivo or in vitro techniques. In the 
first category, the humans or animals are subject to stimuli that are applied in their tongues. These 
studies include human taste panel studies, electrophysiological methods and animal preference tests 
(Uchida and Yoshida, 2013). The other approach is based in indirect methods for assessing the taste 
of the product, measuring some parameters of the final product that are in some way related to taste. 
These methods include drug release studies, surface characterization techniques and also taste 
sensors, like for example, the electronic tongue (Anandet al., 2007).  
A brief description, main advantages and limitations of each approach for the evaluation of taste masking 
formulations, are evidenced in table 3.1. 
 
Table 3.1 In vitro and in vivo approaches for taste masking assessment (Anand et al., 2007; Hughes, 2010; 
Rachid et al., 2010). 
Method Description Pros Limitations 
Taste panel studies 
Taste evaluation 
in healthy human 
volunteers 
Well-established method; 
 
Applies to all taste 
masking techniques; 
Subjectivity; 
Time Consuming; 
Human ethical considerations; 
Representative subjects; 
Low throughput; 
Lack of analytical standardization; 
Expensive. 
Electrophysiological 
methods 
Response 
measurement to 
nerve stimulation 
of an anesthetized 
animal 
Evaluation of taste 
difference; 
 
Screening of new 
chemical entities (NCEs). 
Require surgery; 
Investment on equipments; 
Difficult interpretation and analysis; 
Low throughput; 
Animal Ethical considerations. 
Animal taste 
preference tests 
Analysis of animal 
behavioral when 
subject to bottle 
preference and 
conditioned taste 
aversion tests 
Screening of NCEs by 
evaluation through 
animal preference. 
Qualitative test; 
Low throughput; 
Animal Ethical considerations; 
Expensive. 
In vitro drug release 
studies 
Measurement of 
the quantity of API 
released in a 
specific period of 
time 
No subjectivity; 
Low cost; 
Quality control; 
Applied for novel/special 
dosage forms (such as: 
semi-solid dosage forms 
and transdermal). 
Restricted to methods that reduce 
the buccal exposure of the drug 
(coating, IERs and cyclodextrins 
(CD’s)); 
Can’t be applied in liquid 
formulations. 
Surface 
characterization 
techniques 
Elemental 
chemical 
mapping/ 
quantification of a 
specific element 
No subjectivity; 
Determination of the EE. 
Some techniques-drug dependent; 
Expensive; 
Difficult analysis and interpretation; 
Can’t be applied in liquid 
formulations. 
Electronic sensor 
Methods 
Measurement of 
an electrical 
potential across 
different 
membranes 
 No subjectivity; 
Assess the bitterness of 
NCEs; 
Applied to any taste 
masking technology. 
Difficult interpretation and analysis; 
Require the development of a 
model; 
Equipment needed more expensive. 
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3.1. Taste Panel Studies 
 
The work done in panelist tests assessment, reported by several authors, used different taste masking 
strategies with different APIs formulations and dosage forms (table 3.2). As far as the information 
presented in the table is concerned, the ages of the small group (6-20 people) of healthy human 
volunteers vary between 18 and 29 years (Maniruzzaman et al. 2012; Sadrieh et al. 2005). It is also 
important to take into account their nationality and eating habits for the significance of the results i.e., to 
ensure a highly representation of the target population as discussed by Hughes (2010). 
The taste quality and intensity of the tastants are evaluated by the attribution of different adjective scales 
or scores. The majority of the scales uses numeric systems (Liew et al., 2012; Lorenz et al., 2009), but 
there are some scales that use other scoring systems: for example, Singh et al. 2012 uses the signals 
– and + that represent no taste masking and completely taste masking formulation. Thus, a certain 
subjectivity is inherent to this method, since the results are dependent on the appreciation of people that 
made part of the panel test, as well as safety, economical and human ethical concerns. 
Before determining taste masking properties, it is necessary to fulfill the train of the panelists (Albertini 
et al. 2004; F.M. Mady et al. 2010) and determine the threshold concentration of the API (Albertini et al. 
2004; Bora et al. 2008) to ensure the panel results and their reliability.  
A huge advantage of this assessment technique comparing to others, is the fact that it can evaluate 
dosage forms produced through several taste masking strategies, for example, double emulsion 
evaporation solvent (Chiappetta et al., 2009), granulation processes (Albertini et al., 2004), coating 
(Shahzad et al., 2011) and coacervation method (Shrotriya et al., 2013). 
Among the different studies shown in the table, it can be seen that the administration of the oral dosage 
form is very distinct as a solution, dispersion or a tablet placed on the tongue depending on the final 
purpose of the medication. Beyond that, the time points of evaluation are very distinct from study to 
study, but generally the dosage form is held in the mouth for given periods of time. 
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Table 3.2 Previous work done in taste panelist evaluation (RDT – Rapidly-Disintegrating Tablets, ODT – Orally Disintegrating Tablets, DRC – Drug Resin Complex, DPC – 
Drug Polymer Complex, N – number of panelists, n.s. – not specified). 
API 
Dosage 
Form 
Taste-masking 
strategy 
Panelists 
Perception 
threshold 
(mg/ml) 
Panelist 
Training 
Dose 
of the 
sample 
(mg) 
Administration 
of the solid oral 
dosage form 
Time point 
of 
evaluation 
Taste-masking 
assessment 
procedure 
Ref. 
acetaminophen Granules 
Use of different 
granulation 
processes 
N: 6 
Age: n.s. 
Sex: n.s. 
1,08 Yes 22,5 
As solution 
(granules are 
dissolved over 3 
min) 
After the 
solution was 
held in the 
mouth for 5 s 
Scoring of pure 
API solution 
against solution of 
the formulation 
(Albertini et 
al., 2004) 
dextromethorph
an 
hydrobromide 
Granules 
Formation of 
DRC with Ionex 
QM 1011, Ionex 
WC 23 and 
Kyron T-114 
N: 6 
Age: n.s. 
Sex: n.s. 
0,04 n.s. 15 
One granule 
placed onto the 
tongue 
After the 
granule was 
held in 
mouth for 2, 
10 and 60 s 
Bitterness score 
using a numerical 
scale 
(Sana et al., 
2012) 
diclofenac 
sodium 
ODT 
Addition of 
Mannitol, 
saccharine, 
MCC, 
croscarmellose 
sodium and 
magnesium 
sterate 
N: 12 
Age: n.s. 
Sex: n.s. 
n.s. n.s. 500 
One tablet 
placed onto the 
tongue 
Immediately 
after 
administratio
n and at 
several 
intervals for  
10 min 
“Time intensity 
method” followed 
by bitterness 
scores 
(Sona et al., 
2011) 
dihydroartemisin
in 
Granules 
Use of different 
coating 
materials 
N: 6 
Age: n.s. 
Sex: n.s. 
0,8 Yes 35 
As solution 
(granules are 
dissolved over 2 
min) 
After the 
solution was 
held in the 
mouth for 5 s 
Scoring of pure 
API solution 
against solution of 
the formulation 
(Shahzad et 
al., 2011) 
doxycycline Tablets 
Addition of 
mixing agents 
N: 20 
Age: 20-
29 
Sex: m/f 
n.s. n.s. 100 
As crushed 
tablet, mixed 
with masking 
agents 
After 
administratio
n (10 s) and 
after 
swallowing 
(1 min) 
Palatability scores 
(Sadrieh et 
al., 2005) 
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indivanir 
Micropart
icles 
Prepared by 
w/o/o double 
emulsion solvent 
evaporation 
N: 10 
Age: n.s. 
Sex: n.s. 
0,02-0,045 n.s. 100 As solution 
Held in the 
center of the 
tongue by 1 
and 5 min for 
20 s 
Bitterness score 
using a numerical 
scale 
(Chiappetta 
et al., 2009) 
promethazine 
hydrochloride 
FDT 
Addition of 
Camphor 
(sublimating 
agent) and 
Mannitol (diluent) 
N: 6 
Age: n.s. 
Sex: n.s. 
n.s. n.s. 150 
One tablet 
placed onto the 
tongue 
Immediately 
after 
administratio
n and at 
several 
intervals for 
15 min 
“Time intensity 
method” followed 
by bitterness 
scores 
(Kolhe et al., 
2013) 
rizatriptan 
benzoate 
(RZBT) 
Dispers
ible 
tablet 
Formation of 
RZBT-CD Binary 
Systems of 
inclusion 
complexes 
N: 6 
Age: 22-
27 
Sex: 
3f/3m 
0,35 n.s. 10 
As dispersion 
(one tablet 
dispersed in 10 
ml water) 
Held 1 ml of 
the 
dispersion in 
the mouth 
for 30 s 
Bitterness score 
using a numerical 
scale 
(Birhade et 
al., 2010) 
sitagliptin 
phosphate 
monohydrate 
RDT 
Formation of DRC 
with addition of 
Indion 414, 
crospovidone, 
croscarmellose 
sodium, sodium 
starch glycolate 
N: 11 
Age: n.s. 
Sex: n.s. 
n.s. n.s. 100 
One tablet 
placed onto the 
tongue 
Immediately 
after 
administratio
n and at 
several 
intervals for 
15 min 
“Time intensity 
method” followed 
by bitterness 
scores 
(Surinder et 
al., 2013) 
sumatriptan 
succinate 
Granul
es 
Addition of 
Eudragit E-100, 
𝛽 −CD and 
sweetener 
N: 12 
Age: n.s. 
Sex: n.s. 
n.s. n.s. 
Depend 
on TM 
strateg
y 
Granules placed 
“on posterior 
lobe of tongue” 
After 
administratio
n (4-6 s) 
Taste-masking 
and grittiness 
evaluation 
(Singh et al. 
2012) 
tramadol RDT 
Formation of DPC 
by coacervation 
method with 
addition of 
Eudragit EPO and 
sodium hydroxide 
N: 20 
Age: 20-
25 
Sex: n.s. 
0,02 n.s. 50 
As dispersion (1 
g Tramadol 
dispersed in 50 
ml water) 
Held 1 ml of 
the 
dispersion in 
the mouth 
for 30 s 
Bitterness score 
using a numerical 
scale 
(Shrotriya et 
al., 2013) 
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3.2. Electrophysiological Methods 
 
Katsuragi et al. (1997) focused their attention in a method for inhibit the human taste sensation to bitter 
tastants and suggested, through the use of Bullfrogs (Rana catesbeiana), that a lipoprotein called PA-
LG (composed by PA and 𝛽-LG) suppressed selectively the taste responses, as a result of a complex 
formation, with certain type of bitter tastants in the medium. 
Other interesting study, led by Sato et al. (2010), was the response to cold and warm stimuli measured 
by a receptor potential of frog taste cells, which showed that this type of cells are sensible to thermal 
stimuli of 5-35 ºC, leading to depolarizing and hyperpolarizing of the receptor’s potentials. The authors 
found that during a warm stimulation of the frogs’ tongue, they can perceive thermal sweet responses, 
due to a correlation between depolarizations by warm stimuli of 30 ºC and depolarizations induced by 1 
M sucrose of 20 ºC. 
 
3.3. Animal Preference Tests 
 
Tiwari et al. (2015) investigated the palatability of caffeine citrate formulation produced by HME 
technology using 21 rats. They were submitted to privation of water for 22 h to stimulate the response 
to thirst, then they had free access to water (or formulations with different concentrations of the API) for 
a period of 30 min, followed by the removal of the bottles. The volume consumed from the bottle was 
recorded, as well as the taste aversion behaviors of rats, resulting of responses to the bitter-taste stimuli 
such as retreating, jaw smacking, nose wrinkle, head shake, paw shakes and oral grooming. 
The rats’ behavior and the volume consumed of the solutions suggested that they didn’t appreciate the 
taste of the solution with the pure API and all the taste masked formulations tested, showed effective 
taste masked effect.   
Also Noorjahan et al. (2014) performed a similar study and even a taste assessment by human 
volunteers, obtaining a good correlation between the behaviors that were verified in rats and humans. 
 
3.4. In vitro Drug Release Studies 
 
During taste masking assessment by in vitro drug release studies, it is critical to assure that the 
dissolution method is able to mimic the oral cavity in terms of composition of the dissolution medium, 
pH, temperature, volume and agitation (Gittings et al., 2014). Attending to the International 
Pharmaceutical Federation/American Association of Pharmaceutical Scientists (FIP/AAPS) guidelines, 
the selection of the suitable apparatus is also important since it simulates the hydrodynamics of human 
body, although it is also necessary to take into consideration the type of dosage form and its physical 
and chemical properties (Santos, 2012). Thus, for oral dosage forms, the apparatus of first choice is the 
Apparatus 2 (paddles). 
In figure 3.1, an illustration of a paddle apparatus is shown, as well as a schematic representation of the 
dimensions/distances related to the vessels, that are stipulated in the International Pharmacopeia 3rd 
Edition. 
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Figure 3.1 Illustration of a paddle apparatus (a) and schematic representation of the recommended dimensions 
and distances (in mm) related to the vessels (b) (adapted from (Paleshnuik, 2009)). 
 
As illustrated in the previous figure, the vessel must have specific dimensions, which should be 
invariable from vessel to vessel to assure the reliability and reproducibility of the dissolution tests. To 
start the dissolution study, the sample should be introduced and deposited in the vessel´s bottom before 
stirring, usually between 50-75 rpm. If the oral dosage form has the tendency to float, it is convenient 
the use of an appropriate dispositive called sinker, that will be able to fix the oral dosage form (Stippler, 
2011).  
The sample collection is performed in the middle of the vessel to assure that only the dissolved solution 
is collected and not the drug that will dissolve over time, in the vessel’s bottom. Furthermore, the 
sample´s volume removed can be reestablished by adding the same volume of dissolution medium. If 
the replacement of the dissolution medium is not performed, it is necessary to take into consideration 
the volume variation that occurred in the calculations of the dissolution velocity (Santos, 2012). 
In terms of the dissolution media, typically research groups used a single one (Albertini et al. (2004) ; 
Mady et al. (2010)), namely: phosphate buffer solution (PBS) at different pH values 6.8, 7.4 (F. Q. Li et 
al., 2010), and 7.5 (Vaassen et al., 2012) and also simulated saliva fluid (SSF) at pH 6.2 (Yan et al. 
2010) and 7.4 (Guhmann et al., 2012). Other common dissolution medium is water (Shirai et al. 1994) 
once it is the most abundant and economic solvent. Frequently a surfactant, such as Tween 80 
(Mizumoto et al., 2008) and polysorbate 80 (Hamashita et al., 2007), is added to improve the wettability 
of the taste masked particles. 
According to the studies shown in table 3.3, the volume used for the dissolution tests, ranges from 50 
to 900 mL, nevertheless the volume of saliva in the mouth is typically less than 1.5 mL (Lagerlof and 
Dawes, 1984); so the use of such larger volumes, may not be representative when it comes to estimate 
the quantity of drug released. Despite that, it may be reasonable to use volumes of 200-300 mL when 
the dosage form requires the ingestion with a glass of water (Gittings et al. 2014). 
The FIP/AAPS guidelines established general criteria, consisting in the use of a neutral medium where 
the API dissolves usually less or equal to 10 % in 5 min to achieve taste masking. As far as it depends 
on the intensity of the bitter taste of API, a multi-point profile with early time-points of analysis (e.g. < 5 
min) (Siewert et al., 2003) is recommended. For this purpose, Anand et al. (2007) argued that taste 
masking is achieved when, until the first 5 minutes, the API is not detected or its quantification is below 
the threshold limit. As presented in table 3.3, the authors that follow this criteria are a minority.  
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The dissolution methods have been evolved over time, SHIRAI et al. (1996) used a simplified  dissolution 
method that consists in mixing fine granules of sparfloxacin (SPFX) in 10 mL of distillated water in a 10 
mL syringe, agitating it by revolving the syringe end to end five times within 30 s. More recently, Kondo 
et al. (2011) used an equivalent method for coated paracetamol granules, but in this case the agitation 
was given by 10 repeat syringe inversions over 30 s.  
For the evaluation of the taste masking efficiency of clarithromycin, Yajima et al. (2002) suggested a 
more sophisticated dissolution method, that operates in a continuous flow system. The system is 
described as a mini column (that contains the powder) in which the dissolution medium (phosphate 
buffer at pH of 6.5) is injected at different flow rates using a syringe pump, and the final sample collected 
in a small vessel. The authors concluded that better results were obtained by using this method, in terms 
of correlations between sensory analysis and in vitro studies, when compared with shaking, inversion 
or paddle methods. 
The quantification of API in the dissolution medium at each time point is performed by HPLC (high 
performance liquid chromatography) or UV (ultraviolet) spectroscopy. The first is usually preferred in 
the presence of UV-absorbing components (for example, sweeteners) and since UV estimation can be 
difficult sometimes in terms of distinguishing the signal from the background, especially when the ratio 
excipient-drug is high. (Anand et al., 2007).   
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Table 3.3 Previous work done in vitro assessment of taste masking (RDT – Rapid Disintegrating Tablet, ODT – Orally Disintegrating Tablets; SSF- Simulated Salivary Fluid, T – 
temperature, V-volume, AS – Agitation Speed; n.s. –not specified). 
API 
Dosage 
Form 
Taste Masking 
Strategy 
In vitro 
assessment 
tool 
Taste Masking 
criteria 
Dissolution 
settings 
Drug 
dose 
(mg) 
Sample 
(pre)treatment 
Sampling 
timepoint 
Ref. 
acetaminophen Granules 
Preparation by 
different 
granulation 
techniques 
UV 
spectroscopy 
(243 nm) 
Drug release of 
pure API> release 
of taste masked 
formulations 
V: 900 mL 
M: phosphate buffer 
pH: 6.8 
T: 37 ± 0.1 ºC 
AS: 50 rpm 
Apparatus: paddle 
22,5 
Dissolution in 
paddle apparatus 
according to 
USP24 (12,5 
ml/min) 
3 min 
 
(Albertini 
et al., 
2004) 
brompheniramin
e maleate 
Capsules 
Formation of 
complexes with 
tannic acid, 
prepared by the 
solvent 
evaporation 
method 
HPLC 
Drug release of 
pure API> release 
of taste masked 
formulations 
 
V: 500 mL 
M: phosphate buffer 
(0.2 M) and HCl 
buffer (0.1 N) 
pH: 6.8 
T: 37 ºC 
AS: 50 rpm 
Apparatus: paddle 
12 
Dissolution in 
paddle apparatus 
according to USP 
II 
n.s. 
(Rahman 
et al., 
2012) 
cetirizine 
dihydrochloride 
Micropart
icles 
Entrapment of 
microparticles 
within chitosan 
nanoparticles 
followed by 
microencapsulat
ion using SD 
HPLC 
Drug release of 
pure API> release 
of taste masked 
formulations 
V: 100 mL 
M: phosphate-
buffered saline 
(PBS) 
pH: 7.4 
T: 37 ± 0.5 ºC 
AS: 50 rpm 
20 
Microparticles 
placed into a 
membrane 
dialysis bag 
15 min 
(F. Q. Li et 
al., 2010) 
diclofenac (acid 
form, sodium and 
potassium salt) 
Granules 
Coating with 
Eudragit EPO 
through fluidized 
bed followed by 
wet granulation 
HPLC 
Drug release of 
pure API> release 
of taste masked 
formulations 
V: 50 mL 
M: SSF 
pH: 7.4 
T: 37 ± 0.5 ºC 
AS: 50 rpm 
232,5  n.s. 
0,5;1;1,5;2;
2,5 and 3 
min 
(Guhmann 
et al., 
2012) 
famotidine RDTs 
Preparation of 
binary (drug-𝛽-
CDs) and 
ternary systems 
UV 
spectroscopy 
(269 nm) 
Drug release of 
pure API> release 
of taste masked 
formulations 
V: 900 mL 
M: phosphate buffer 
pH: 6.8 
T: 37 ± 0.5 ºC 
20 n.s. 5 min 
(Mady et 
al. 2010) 
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(drug-𝛽-CDs-
Povidone K30) 
through 
kneading and 
freeze-drying 
methods 
Comparison of 
drug release 
between binary 
and ternary 
systems 
AS: 50 rpm 
Apparatus: rotating 
paddle 
ibuprofen ODT’s 
Coating with different 
polymers, addition of 
sweetener  and 
superdisintegrants 
UV 
spectroscop
y (220 nm) 
Drug release of 
pure API> release 
of taste masked 
formulations 
V: 500 mL 
M: phosphate buffer 
pH: 6.8 
T: 37 ± 0.1 ºC 
AS: 100 rpm 
Apparatus: paddle 
700 
Sample filtration 
(5 ml) before off-
line detection. 
10 min 
 
(Fini et al., 
2008) 
mefloquine 
hydrochlorid
e 
Micropa
rticles 
Prepared by 
coacervation method 
using Eudragit EE and 
sodium hydroxide as 
precipitant 
UV 
spectroscop
y (284 nm) 
Drug release of 
pure API> release 
of taste masked 
formulations 
V: 900 mL 
M: phosphate and 
HCl buffer 
pH: 6.8 and 1.2 
T: 37 ± 0.5 ºC 
AS: 75 rpm 
Apparatus: paddle 
250 
Dissolution in 
paddle apparatus 
according to USP 
XXIV 
1, 5 min 
until 60 
min 
(Shah et 
al., 2008) 
NPX 1210 
Lipid 
based 
pellets 
Lipid formulation (lipids 
function as taste 
masking agents) 
UV 
spectroscop
y (295 nm) 
< 5% drug release 
within 2 min 
V: 900 mL 
M: potassium 
dihydrogenphospha
te buffer 
pH: 7.5 
T: 37 ± 0.5 ºC 
AS: 75 rpm 
Apparatus: paddle 
50 % 
drug 
load 
Dissolution in 
paddle apparatus 
according to 
USP33 Method 2 
Drug 
release 
after 2 min 
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3.5. Electronic Sensor Methods 
 
The concept of electronic tongue was proposed to mimic the functions of humans gustatory receptors 
by Hayashi et al. 1990 and K. Toko et al. 1994 in the 90’s. 
Murray et al. (2004) used a consensus classification to check the three different phases of biological 
taste recognition by an e-tongue: the receptors (in humans are called taste buds, in the e-tongue are 
probe membranes), the circuit (in humans is performed by neural transmission, in the e-tongue by a 
transducer) and the perceptual phase (in humans is performed by a cognition in the thalamus, in the e-
tongue by a computer and a statistical analysis). 
The concept of this technique is based on interaction of the sensors with the tastants at the surface, 
resulting in alterations that can be measured, for example potentials and voltages if used potentiometric 
or voltammetric sensors, respectively (Zou et al., 2015). These signals are compared and evaluated on 
the data basis of the sensor responses that are recorded in the computer (Latha and Lakshmi 2012).  
Therefore, an e-tongue is constituted by an automatic sample, an array of chemical sensors with 
different selectivity, instrumentation to capture the signal and a software with a developed algorithm 
able to process the signal and generate results (Escuder-Gilabert and Peris, 2010). 
Rachid et al. (2010) demonstrated that the electronic tongue can be an important tool in taste masking 
evaluation for an intensely bitter substance. In their study, they had shown that the e-tongue can identify 
the agent that best masks the bitter taste of the epinephrine bitartrate. They developed and validated a 
bitterness standard model, obtaining correlation coefficients above 80 %. They also determined the 
threshold concentration of the e-tongue sensors and concluded that the formulation with 9 mM of EB 
and 0.5 mM of citric acid was the best formulation in terms of taste masking effects, since it cannot be 
detected by the sensors of the e-tongue.  
The taste masking effects of formulations of doxycycline mixed with different masking agents were 
evaluated by Sadrieh et al. (2005) through an electronic tongue using seven sensors. The criteria used 
for taste masking was based on group distances calculated by the electronic tongue between placebo 
samples (matrix only) and drug formulations. Accordingly, the best masking agent is identified through 
the smallest group distance, which suggests that the two tastes aforementioned (placebo and drug 
formulations) are more similar. Therefore, they have concluded that the low-fat chocolate milk was the 
best food matrix for doxycycline, with better taste masking efficiency. 
 
3.6. Surface Characterization Techniques 
 
Surface characterization has been widely studied in several areas such as metallurgy, corrosion, among 
others. The use of these techniques had a huge increment since the researchers realized that the future 
of the materials is composite, i.e. a mix of different materials, and for that reason is important to 
understand the properties of the material surfaces that will be in contact with each other. Hence, there 
are an innumerous number of techniques that are used with the purpose of characterize the surface of 
the materials, such as SEM-EDS, XPS, High Resolution Electron Energy Loss Spectroscopy (HREELS) 
and Auger Electron Spectroscopy (AES) (Rego, 1993). 
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3.6.1. Scanning Electron Microscopy – Energy Dispersive Spectroscopy (SEM-EDS) 
 
SEM is a technique based on the creation of micro-imaging of an innumerous surface’s materials, 
making possible to study the texture of that surface and determine the particle size. The interaction of 
the electrons, from the electron beam that is focused on the sample, with the different atoms presented 
in the sample produce several types of signals (secondary electrons, x-rays, auger electrons). These 
signals are then collected by the detectors, amplified and used to modulate the intensity of a select X-
ray line, and finally, the scanning of the beam is synchronized and electron images are originated 
(Zunbul, 2005).  
Energy Dispersive X-ray Spectroscopy is a powerful tool when associated with SEM, allowing not only 
to determinate the elemental composition of surfaces but also its elemental quantification. The principle 
of the technique is grounded on the emission of x-rays by the sample as a response of the electron 
beam, generating peaks at specific energies, according to the elements that the sample contains since, 
each element has a unique atomic “digital impression”; the concentration of the elements are determined 
through the integration of the peak are (Canli, 2010; Peterson, 2011).  
In this work, EDS was used to study the elemental composition on the particles surface and to quantify 
the elements that were present, in particular nitrogen, in order to determine the EE. 
 
3.6.2. X-Ray Photoelectron Spectroscopy (XPS) 
 
The XPS technique provides information about the atomic composition of the surface, nature and 
connection of atoms, and is considered the main technique used in surface characterization (Gonçalves, 
1999). 
The concept of this technique is similar to the EDS, however in this case the photoelectrons that 
contribute for the resulting peaks in XPS are the ones that are produced near the surface and without 
loss of energy, i.e. the identification of the elements is performed from the kinetic energies of ejected 
photoelectrons (Barros, 2009). 
The output of XPS are spectra as a function of the binding energy of the electrons from the inner layers 
of the atoms (Ferraria, 2002).   
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4. Materials and Methods 
 
4.1. Materials 
 
The model drug used in this work is an API produced by Hovione Farmaciência SA. A commercially 
available polymer, Methacrylic Acid and Methyl Methacrylate Copolymer (1:2) (Eudragit® S100, Evonik 
Röhm GmbH, Darmstadt, Germany) was selected as an excipient. The selection of the polymer was 
based on an enteric polymer that dissolves at pH>7, to assure that when in contact with the salivary 
fluid within the oral cavity it doesn’t dissolve protecting the core material, since the salivary pH varies 
between 6.7-7.4 (Hans et al., 2016). The antisolvent and solvent used were deionized water and DMF, 
respectively, both of an analytical grade. To acidify, a 37 wt. % hydrochloric acid solution (Sigma-Aldrich, 
Missouri, USA) was used, in order to force the polymer to precipitate (antisolvent effect).  
 
4.2. Methods 
 
The production process was divided into two steps, followed by powder characterization: production of 
co-precipitated suspensions and isolation of the suspensions by spray drying and analytical 
characterization of the co-precipitated spray-dried powders. The first stage of the process started with 
the planning of the DoE, described in subchapter 4.2.1., which was conducted to produce the co-
precipitated suspensions through several technologies: conventional approach (stirred reactor), Covaris 
technology and PureNano. The operational conditions used for each technology are described in detail 
in subchapters 4.2.2/3/4. The second step of the process is designated as an isolation step of the co-
precipitated suspensions, based on the drying of the suspensions through SD in order to obtain co-
precipitated spray-dried powders. The operational conditions are described in subchapter 4.2.5. Finally, 
after obtaining the final powder it was necessary to evaluate the CQAs, in this case API solid state form, 
particle size and morphology and in vitro dissolution. The powders were characterized by diverse 
analytical techniques, such as: SEM-EDS, XPS, XRPD (X-Ray Powder Diffraction), DSC, TGA 
(Thermogravimetric Analysis), UPLC (Ultra-Performance Liquid Chromatography) and in vitro 
dissolution. The methods used for each technique are described in subchapters 4.2.6 until 4.2.15. 
 
4.2.1. Design of Experiments  
 
A 23 full factorial design of experiments was designed with the aim of studying the effect of formulation 
variables on CQAs of powders produced by co-precipitation. The formulation variables studied were: 
the SAS volume ratio (1:6, 1:8 and 1:10), the drug load (30, 45 and 60 % w/w) and the feed solids 
concentration (8, 10 and 12 % w/w), as described in table 4.1. and figure 4.1(a). 
Preliminary studies performed with the stirred reactor indicated that for drug loadings lower than 45 % 
occurs the formation of polymer filaments; for that reason, only one face of the cub was considered 
corresponding to a constant drug load of 60 %, as shown in figure 4.1(b).  
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Table 4.1 Experimental design for the co-precipitation stirred reactor process study. 
 
 
 
 
 
 
 
 
 
 
 
 
4.2.2. Batch Stirred Reactor 
 
For the application of the DoE 4 solutions were prepared, corresponding to trials #3, #4, #7 and #8, 
whose SAS volume ratio and feed solids concentration ranged accordingly as described in table 4.1. 
The antisolvent (water) was acidified to ensure that pH ranges from 3 to 4 to enhance the antisolvent 
conditions for the polymer, using a 37 wt. % hydrochloric acid solution. The process took place at a 
room temperature of 25±2 ºC. The co-precipitation occurred in a jacketed stirred lab reactor of 1000 mL 
(Radley, United Kingdom) whose setup is schematic illustrated in figure 2.4. The antisolvent was inside 
the reactor, the solution was added using a peristaltic pump (Watson Marlow 323, Falmouth, United 
Kingdom) at a controlled rate, according to the ratio antisolvent/solvent used and so that the solution 
was added for 10 min. The agitation was provided during 120 minutes by a mechanic stirrer (IKA RW 
20 Digital, Staufen, Germany) with an agitation speed of 181 rpm. Four suspensions were obtained and 
for that reason, the particles were then subjected to an isolation step, being dried in a lab-scale spray 
dryer. 
 
4.2.3. Adaptive Focused Acoustics Technology 
 
A Covaris S120X 1,062 MHz and 42,5 Ω (LGC-KBioscience UK Ltd., Teddington, United Kingdom) was 
used to produce 4 suspensions, corresponding to trials #3, #4, #7 and #8. This approach uses a 
Experience 
Number 
SAS Volume 
Ratio 
Drug load 
(%w/w) 
Feed solids 
concentration (% w/w) 
1 1:6 30 8 
2 1:10 30 8 
3 1:6 60 8 
4 1:10 60 8 
5 1:6 30 12 
6 1:10 30 12 
7 1:6 60 12 
8 1:10 60 12 
9 1:8 45 10 
Figure 4.1 Schematic illustration of the (a) DoE initially designed and (b) DoE adopted for the co-
precipitation stirred reactor process study. 
 
(a) (b) 
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commercially available ultrasonicator. The flow cell was fed with two streams: the antisolvent and the 
solution of API and polymer, by two peristaltic pumps for each stream. The peristaltic pumps were 
calibrated so that the antisolvent flow rate was 6 or 10 times higher when compared with the solvent 
flow rate, according to the SAS volume ratio used for each trial. The streams connect to each other in 
the focal zone, where acoustic waves are conveyed through the water and focused in that specific zone. 
The process described is illustrated in figure 4.2. A preliminary screening study was performed in order 
to fit the values for given parameters. The values that were considered more adequate for the process 
were: 1 000 cycles per burst (CPB), a duty factor (DF) of 50 %, a peak incident power (PIP) of 300 and 
a temperature of 35 ± 5 ºC. In the end, 4 suspensions were obtained, isolated through a lab-scale spray 
dryer and subjected to a post-dry process in a tray dryer oven under vacuum at 20 ºC for 18 hours. 
 
Figure 4.2 Schematic representation of experimental setup with Adaptive Focused Acoustics (adapted from 
(Hanefeld et al., 2015)).  
 
4.2.4. Microfluidization Process 
 
Four solutions of model drug and polymer were prepared in DMF, corresponding to trials #3, #4, #7 and 
#8 whose SAS volume ratio, feed solids concentrations and drug loadings are established in table 4.1. 
The water was acidified with a hydrochloric acid solution in order to obtain a H+ concentration between 
10-3 M and 10-4  M, which correspond to pH 3 and 4, respectively. 
The solvent/antisolvent controlled precipitation experiments were performed using PureNanoTM 
Microfluidics Reaction Technology (MRT, CR5 Reactor model) with the setup that is illustrated in figure 
4.3. Two streams, one with solvent and another with antisolvent are fed into an intensifier pump at 
individually controlled flow rates. The intensifier pump was set at the maximum processing pressure 
which corresponds to 20 kPsi, approximately 1379 bar. The solvent flow rate was calibrated in order to 
maintain the SAS volume ratio, while the antisolvent flow rate was imposed by the pressure of the 
system. 
At the intensifier pump the two streams were pressurized in a combined stream and directed to an 
interaction chamber, which comprises of two mixing chambers: the first, with diameter reaction channels 
of 75 𝜇m (F20Y), followed by another chamber with 200 𝜇m (H30Z). The first chamber had the purpose 
of promoting and intensifying the mixing rate, while the second stabilizes the solution. After the 
interaction chambers, the suspension was delivered to a heat exchanger, to control the temperature 
increase of the resulting suspension. For the 4 trials, only one single passage through the processor 
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was performed. After this, the suspensions were isolated and collected through a lab-scale spray dryer 
and subjected to a post-dry process in a tray dryer oven under vacuum at 20 ºC for 18 hours. 
 
Figure 4.3 Schematic representation of a Microfluidization process, in which results the production of 
suspensions, that are isolated by spray drying. 
 
4.2.5. Spray Drying 
 
To dry the suspensions corresponding to trials #3, #4, #7 and #8 produced by (1) the conventional 
approach; (2) the Covaris technology; (3) the Microfluidics Reactor Technology and (4) an amorphous 
powder of the model drug, a laboratory scale spray dryer (BÜCHI Mini Spray Drier B-290, Switzerland) 
was used, equipped with a two fluid nozzle with a 1.4 mm cap and 0.7 mm tip. The process took place 
in an open cycle mode characterized by the inexistence of a gas recycle unit, as mentioned in chapter 
2.1. The spray dryer was stabilized with gas (nitrogen) and also with stabilization solvent (DMF and 
water, in the same proportion present in the suspension) so that the inlet and outlet temperatures were 
stable. The inlet temperature was adjusted, altering the inlet temperature set point, until achieving an 
outlet temperature of 100 ºC. After this process, the suspensions were permanently mixed, using a 
magnetic stirring system, and simultaneously fed into the nozzle by a peristaltic pump at a flow rate of 
0.29 kg/h, being atomized in the nozzle with a flow rate of 0.96 kg/h. In the spray drying chamber, the 
droplets were dried through a co-current nitrogen stream at a flow rate of 32.5 kg/h. The resulting dried 
particles were directed to a cyclone, being collected at the bottom. The final powder was subjected at a 
post-drying process in a tray dryer oven under vacuum at 20 ºC for 18 hours. 
For the production of the amorphous powder (4), a solution of model drug in DMF with 9 % of feed solids 
concentrations was prepared and the powder was dried according to the following conditions: flow rate 
of drying gas equal to 35 kg/h, atomization feed of 0.925 kg/h, flow rate of 0.28 kg/h and an outlet 
temperature of 100 ºC. 
 
4.2.6. Scanning Electron Microscopy - Energy Dispersive Spectroscopy (SEM-EDS) 
 
The collected samples were examined to study their morphology by SEM; moreover, in order to have 
insights in what concerns the EE, EDS was applied. The particles were fixed to adhesive carbon tapes, 
which are attached to an aluminum plate, and sprayed with pressurized air to remove the excess 
powder. After this process, the aluminum plate, already containing the samples for analysis, was coated 
with gold/palladium (South Bay Technologies, model E5100, San Clement, CA) and introduced in the 
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microscope under vacuum conditions. The micrographs were obtained at several magnifications, 
ranging from 250x to 20 000x, by a JEOL JSM-7001F/Oxford INCA Energy 250/HKL scanning electron 
microscope (JEOL, Tokyo, Japan) that operates at an accelerating voltage of 15 kV.  
The EDS mode allows an elementary characterization and quantification of the periodic elements 
identified in the sample by the microscope. For this purpose, a given area of the sample was selected, 
typically at a magnification of 1000x, to assure that no agglomeration was verified nor that the particles 
were too far apart. 
 
4.2.7. Particle Size 
 
The particle size of the spray dried co-precipitated powders was estimated as the mean circular 
equivalent diameter, through an image analysis software called ImageJ (National Institute of Health, 
Bethesda, MD, USA). 300 particles were randomly selected from each sample, in order to assure a 
normal distribution of the particle sizes. The mean circular equivalent diameter is defined as the diameter 
of a circle that have the same area of the particle manually selected in the micrographs of SEM (Olson, 
2011).  
Using the image analysis software, the area of the particle was measured and then, the mean circular 
equivalent diameter was estimated using the following equation: 
𝑑 =
√4 𝐴
𝜋
 
Equation 4.1 
4.2.8. X-ray Photoelectron Spectroscopy (XPS) 
 
The encapsulation efficiency was also studied through a XPS spectrometer, in particular in a XSAM800 
designed by KRATOS (Manchester, United Kingdom). Samples of trials #7R, #8C and #7P were fixed 
to a double sheet glue, attached on a small aluminum plate. These were then placed in the entry 
chamber, it was necessary to wait until it reached a pressure vacuum in the order of magnitude of 10−7 
Pa. Subsequently, the samples were placed in the analysis chamber with a 45º take-off angle (TOA), 
where the ultra-high vacuum is achieved (pressures of about 10−10 𝑃𝑎). The spectrometer operated in 
the Fixed Analyzer Transmission (FAT) mode, with pass energy of 20 eV. The samples were subject to 
a non-monochromatized Mg Kα X-radiation (ℎ𝑣= 1253.6 eV), produced using a voltage of 12 kV and a 
current of 10 mA. The acquisition of the spectrums was performed through a software called VISION 
version 1.0 designed by KRATOS (Manchester, United Kingdom) and the data files in ASCI format were 
analyzed and processed through a software called XPS peak version 4.1 (Raymond Kwok, Hong Kong, 
China). 
 
4.2.9. X-Ray Powder Diffraction (XRPD) 
 
To evaluate the crystallinity of the powders, XRPD experiments were conducted in a X’Pert Pro 
PANalytical X-ray Diffractometer (Almelo, The Netherlands) using a source of cooper radiation (Cu 
k𝛼=1.5406 A) at a current of 40 mA and a voltage of 40 kV. A Beta-Filter Nickel was used with a 
thickness of 0.020 mm. The preparation of the samples involved pressing the powder in the sample 
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holder, in order to obtain a smooth surface. The samples were subject to the aforementioned radiation, 
over a 2𝜃 interval from 3 to 40 º with a step time of 26 seconds and a step size of 0.0167 º. The resulting 
diffractograms were collected through a software designated Data Collector version 4.1 and analyzed 
through a software called Data Viewer version 4.1. 
 
4.2.10. Differential Scanning Calorimetry (DSC) 
 
The thermal behavior of all powders produced was analyzed through differential scanning calorimetry 
(DSC Q200 V24.4 Build 116, TA Instruments Thermal Analysis, New Castle, USA). About 2-8 mg of 
sample were loaded into an aluminum pan (pinhole hermetic type); the same type of pan was used as 
reference. Continuous dry nitrogen gas at a flow rate of 50 mL/min was employed, and the samples 
were heated from 20 to 300 ºC at a constant heating rate of 10 ºC/min. The DSC thermograms were 
processed and analyzed through a software called Universal V4.5A TA Instruments. 
 
4.2.11. Thermogravimetric Analysis (TGA) 
 
The weight loss related with water and residual solvents that occurred in all the formulations produced 
was determined by thermogravimetric analysis (TGA Q500 V20.10 Build 36, TA Instruments Thermal 
Analysis, New Castle, USA). Some mg of sample were loaded into a platinum pan that was then 
subjected to a heating ramp inside a furnace. The weight loss is determined using as reference an empty 
platinum crucible. Continuous nitrogen gas was employed in the balance and in the sample, at a flow 
rate of 40 and 60 mL/min, respectively. The method used consisted in heating the samples until 350 ºC 
at a heating rate of 10 ºC/min. The TGA thermograms were processed and analyzed through a software 
called Universal V4.5A TA Instruments. 
 
4.2.12. Ultra-Performance Liquid Chromatography (UPLC) 
 
For the quantification of the model drug, a Waters UPLC system (model Acquity UPLC H-Class) was 
used with a dual wavelength absorbance detector (model PDA Detector) (Waters, Milford, USA). The 
column used was an Acquity CSHC18 (100 mm x 2.1 mm, 1.7 𝜇m). The mobile phase consisted of 
50:50 % v/v of Methanol:Dipotassium hydrogen phosphate, the pH being adjusted to 8 with phosphoric 
acid and degassed for 10 minutes in a sonicator bath (VWR Ultrasonic Cleaner USC-THD) before use.  
The injection volume was 1.0 𝜇L and the flow rate was constant at 0.3 mL/min, at a column temperature 
of 40 ºC and an autosampler temperature of 5 ºC. The quantification of the model drug was performed 
at a wavelength of 280 nm, the chromatographs were processed using the software Empower Version 
3.0 (Waters, Milford, USA).  
 
4.2.13. Determination of Encapsulation Efficiency 
 
As previously mentioned, the evaluation of the EE was performed using both SEM-EDS and XPS 
techniques. Based on the data collected in both cases, it was possible to quantify the nitrogen present 
in a given point of the sample and consequently to estimate the EE. Besides the specific samples that 
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were analyzed through these techniques, also some standard samples (pure API and a physical mixture 
of drug/polymer at a ratio 60:40 % wt.) were analyzed in order to compare the intensity of the elementary 
peaks identified by the microscope. Finally, the EE was estimated as indicated in the following equation. 
 
% 𝐸𝐸 =  
 % 𝑜𝑓 𝑑𝑒𝑡𝑒𝑐𝑡𝑒𝑑 𝑁 𝑖𝑛 𝑡ℎ𝑒 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 − % 𝑜𝑓 𝑑𝑒𝑡𝑒𝑐𝑡𝑒𝑑 𝑁 𝑖𝑛 𝑡ℎ𝑒 𝑠𝑎𝑚𝑝𝑙𝑒
% 𝑜𝑓 𝑑𝑒𝑡𝑒𝑐𝑡𝑒𝑑 𝑁 𝑖𝑛 𝑡ℎ𝑒 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑
× 100 
Equation 4.2 
Note that the standard sample used in this equation was the pure model drug, for both EDS and XPS 
analysis. 
 
4.2.14. Drug Content in the formulations 
 
The drug content present in all the formulations was assayed through the UPLC method described in 
section 4.2.12. For all the formulations, solutions with a model drug concentration of 200 𝜇g/mL were 
prepared, weighing about 33.34 mg of each formulation and dissolved in 100 mL of methanol (MeOH) 
in a volumetric flask. The solutions were agitated at 800 rpm in a multi shaker for 5 minutes until they 
were completely dissolved. The quantification of the model drug in the formulations was performed 
against a calibration curve with pure model drug dissolved in MeOH, with concentrations that varied 
from 20 to 200 𝜇g/mL. The drug content of each sample was determined in duplicate, and D-check was 
calculated to assure the reliability of the results. 
 
4.2.15. In-vitro Dissolution Studies 
 
Two approaches were used for these studies: conventional dissolution in 6-well plate and pH shift 
dissolution methods. The purpose of the first approach was to verify the drug release of the formulations 
in the oral cavity, and the second one to understand if the enhanced taste masking properties that are 
expected in the samples didn’t impact its dissolution profile. 
The experiments that correspond to the first approach were conducted in a 6-well plate in an ES – 20/60, 
Orbital Shaker – Incubator (Biosan, Riga, Latvia) at a temperature of 37 ºC and an agitation of 70 rpm. 
In the 6-well plate 10 mL of simulated salivary fluid (SSF) at a pH of 6.75 were placed, being degassed 
for 10 minutes at a sonicator and preheated to 37 ºC before use. The composition of the aforementioned 
medium is described in table 4.2. As the concentration of the model drug was 10 times higher when 
compared to the pH shift approach, these dissolution experiments occurred under non sink conditions. 
Samples of 2 mL were taken at two time points, 5 and 10 min, with dissolution medium replacement. 
The samples were filtered using Acrodisc® 0.45 𝜇m syringue filter with a hydrophilic polypropylene 
(GHP) membrane (PALL Corporation, New York, USA) without discarding the first mL and were diluted 
so that the final concentration stayed within the range of values of the calibration curve. 
In the second approach a Paddle Apparatus (Copley Dissolution Tester DIS 6000, Nottingham, UK) was 
used in a 37 ± 0,5 ºC temperature water bath. The dissolution media consisted of 30 mL of HCl 0,1 N 
and 70 mL of FeSSIF (Fed State Simulated Intestinal Fluid) biorelevant medium 1.3 times more 
concentrated (pH=5) (Biorelevant.com, Croydon, Surrey, UK). The dissolution media were degassed in 
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a sonicator for 10 minutes and preheated to 37 ºC before use. The sink conditions were assured when 
the FeSSIF medium, 1.3 times more concentrated, was added and the quantity weight of the 
formulations was estimated taken into account the drug loading of each formulation. Samples of 3 mL 
were taken at different time points (5, 15, 30, 45, 60, 90, 120, 150 and 180 min) with dissolution medium 
replacement, in the first 30 min using HCl 0.1 N and then normal FeSSIF. The samples were filtered 
using Acrodisc® 0.45 𝜇m syringue filter with GHP membrane (PALL Corporation, New York, USA) 
discarding the first mL and were diluted until the final concentration fell within the range of values of the 
calibration curve. In the beginning, HCl 0.1 N was used as the dissolution media, the pHs of the taken 
samples were adjusted to 8, with ammonium hydroxide, since at this pH the majority of the molecules 
are in the free form, not affecting the residence time in the chromatograms. The pH shift occurred at 30 
min-time point, by adding FeSSIF medium 1.3 times more concentrated. 
The drug released from all formulations at different time intervals was determined by UPLC according 
to the method reported in Section 4.2.12.  
 
Table 4.2 Composition of the SSF media (Koland et al., 2011; Peh and Wong, 1999). 
Components  Quantity Weight 
Disodium hydrogen phosphate 2,38 g 
Potassium dihydrogen phosphate 0,19 g 
Sodium Chloride 8,00 g 
Milli-Q water 1 L 
Phosphoric Acid Enough to adjust pH to 6,75 
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5. Results and Discussion 
 
To produce co-precipitated suspensions, three different co-precipitation processes (Stirred Reactor, 
Covaris and PureNano) were used. Spray drying was applied in order to isolate the suspensions 
produced, obtaining spray-dried co-precipitated powders.  
After the powders production, different analytical characterization techniques (SEM-EDS, XPS, XRPD, 
DSC, TGA, UPLC, Dissolution) were employed to evaluate the CQAs (morphology and particle size, 
solid state and in vitro dissolution performance) and for benchmarking purposes of the co-precipitation 
processes, regarding taste masking properties of the different spray-dried co-precipitated powders.  
 
5.1.  Morphology of the Spray-Dried Co-Precipitated Powders 
 
SEM micrographs for the spray-dried co-precipitated powders corresponding to trials #3, #4, #7 and #8 
of the DoE (in figure 4.1) performed using three different technologies are presented in figure 5.1. 
As the micrographs show, in general, for all the formulations tested spherical particles were obtained, 
independent of the technology used for the co-precipitation process. This type of morphology is 
characteristic of the isolation process selected for all the suspensions produced - spray drying (Passos 
and Birchal, 2010; Vehring, 2008). This type of morphology is frequently encountered for taste masking 
purposes, due to the low cost of SD production; furthermore, a high level of protection and controlled 
release is provided to the core material entrapped within the microsphere (Oxley, 2016).   
 
Figure 5.1 SEM micrographs corresponding to trials #3, #4, #7 and #8 of the DoE performed in the stirred reactor 
approach (#R), Covaris technology (#C) and PureNano technology (#P). Note that the bigger micrographs were 
taken at a magnification of 2 500x, while the smallest micrographs were taken at a magnification of 20 000x. 
 
At higher magnifications it is possible to see the surface of the particles, revealing in the majority of the 
trials, a smooth surface and inflated particles. According to Vicente and Ferreira 2015 and Dobry et al. 
#3R #4R #8R#7R
#3C #4C #7C #8C
#3P #4P #7P #8P
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2009, if starting from a solution, this type of structure suggests that a fast drying possibly occurred as a 
result of a high T_out that is near or above the boiling point of the DMF, when the droplet skin is formed. 
Thus, when the particle dries, the vapor pressure keeps it “inflated” leading to a hollow-sphere 
morphology. Typically, this type of morphology is characterized as having a low bulk density and a low 
percentage of residual solvent.  
However, in this particular case the starting point of SD was a suspension, so it’s necessary to be careful 
with the conclusions drawn. Starting from a suspension in SD, there will always exist a residual solubility 
that will act as a glue between the particles, as the solvent is evaporated in SD process, forming 
agglomerate structures. These agglomerate structures can be seen in some micrographs, and are 
specially noted in micrograph of the trial #7R. In some micrographs, namely #3C, #3R, #3P, #4P, #7P, 
#7C and #8C it is possible to distinguish some particles that present a rough surface as a result of a 
possible slower and/or deficit drying. 
The micrograph corresponding to trial #4C reveals a warning that probably the EE and consequently 
taste masking effect could have been compromised, since it detects, in a representative form in the 
sample, the presence of API particles at a crystalline form on the surface of the spherical microparticles. 
Also, trial #7C seems to present crystalline pure drug on the surface of the spherical particles. 
Nevertheless, for this case, it is not representative of the sample. 
If we look more carefully at the micrographs at a magnification of 20 000x, e.g. for #3C, #4R, #8R, #7P, 
#8P, #8C, but specially for trial #7R, it can be concluded that the surface of the particles is a result of 
the aggregation of multiple single primary particles. Most of these particles have a mean diameter that 
ranges in the nanoscale. Therefore, it is possible to conclude that in the co-precipitation process used, 
the suspensions can be classified as nanosuspensions, nevertheless when SD is applied as an isolation 
step, the particles aggregated as submicronparticles followed by the encapsulation of a polymer layer, 
hopefully, forming an almost perfect sphere. This type of structures is probably a result of the formation 
of crystalline solid dispersions, crystalline drug within an amorphous polymeric matrix. Therefore, the 
type of particulate structure obtained may not be hollow, typically as a result of SD, but probably inside 
will present a certain level of compaction. 
With regard to the aggregation of the particles and considering the micrographs #3R and #7R, #3C and 
#7C, #4C and #8C, #4P and #8P that are distinguished by the increase of the feed solids concentration 
from 8 to 12 % wt., it perceives a higher degree of particles aggregation. These results can be explained 
by an increase in population density, i.e., number of particles in solution, leading to an increase in the 
agglomeration rate, according to Thorat and Dalvi, 2011. For trials #3P and #7P, #4R and #8R no 
significant differences were detected. 
In terms of SAS volume ratio, the degree of aggregation does not appear to be significantly impacted, 
since when it compares with the micrographs #3C and #4C, #3R and #4R, #3P and #4P, #7C and #8C, 
#7P and 8P no significant differences are detected. The exception is micrographs #7R and #8R, in which 
a higher degree of aggregation in the first micrograph mentioned was verified. This can be related with 
a low agitation speed resulting in an insufficient mixing capacity that leads to an excessive nucleation 
and, consequently, formation of highly agglomerated products (Yu et al., 2005). 
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Nevertheless, it is important to note that a great number of scientific publications claim that the amount 
of polymer stabilizer in the formulation is the main cause for the particles aggregation phenomena, and 
that the addition of polymer stabilizers inhibits the excessive crystal growth and subsequently facilitates 
particle aggregation (Ali et al., 2011; Ghosh et al., 2011; Meer et al., 2011). Also, the SD isolation step  
is referred in literature as a possible factor of increasing the particles aggregation, thus several research 
groups have been studying different approaches to prevent secondary aggregation during SD (Kumar 
et al. 2014; Lu 2014).   
 
5.2.  Particle Size of the Spray-Dried Co-Precipitated Powders 
 
The mean circular equivalent diameter (MCED) of the powders produced was roughly estimated as 
indicated in subchapter 4.7, and are represented in 𝜇m in figure 5.2. 
In general, among all the technologies used, the MCED varies from 0.84 𝜇m to 1.57 𝜇m and it seems 
to be homogeneous independent on the technology used, with similar particles size being observed. 
According to the high standard deviations observed in figure 5.2, it is not possible to distinguish the 
different technologies used regarding the MCED. The use of other techniques based on laser light 
diffraction would allow more accurate determinations of the particle size.  
In figure 5.2, it can be observed that when comparing trials 3 to 7 and trials 4 to 8, i.e., increasing the 
feed solids concentration, the MCED remain practically constant.  
According to Park and Yeo, 2012, a decrease on the PS with the increase of the drug concentration in 
solution was expected - as a result of higher supersaturation levels, increasing the nucleation rate that 
leads to the formation of a large number of smaller nuclei and consequently, smaller crystal size  
However, in this case, the result obtained can be explained by the fact that not only the drug 
concentration was increased but also polymer concentration, and both were increased similarly. 
Moreover, it was not possible to increase the initial feed solids concentration more in order to keep the 
solubility of the model drug below its limit and to maintain the SAS volume ratio. It should also be noted 
that the only exception for the trend aforementioned was trials #4P to #8P, where a significant increase 
in the MCED value was observed.  
Though is not possible to draw particular conclusions, regarding to the state of the art, it would be 
expected to obtain a smaller PS and a narrow PSD for Covaris technology (Dhumal et al. 2009; Narducci 
et al. 2011; Patel and Murthy 2011), and Microfluidization.  
For both technologies, the elevated mixing capacity is responsible for the disruption of the agglomerates, 
reducing the PS and PSD (Yu et al., 2005). In the first case, the high shear mixing promoted by the 
Ultrasound treatment is increased about 10 times in comparison with the mechanical stirrer (Kim et al., 
2002). Thus, enabling a further reduction of the powders PS, since a rapid mixing will allow to achieve 
a higher supersaturation degree in a short period of time, which is a key issue in nanoparticles (NPs) 
formation (Thorat and Dalvi, 2011). In case of the microfluidizer, the process pressure determines the 
energy dissipation, additionally impacting the PS of the formulations, generally through its reduction 
(Panagiotou et al. 2009; Peltonen et al. 2016). This even may occur since the liquid streams are forced 
to form turbulent and opposite jets with high velocities, forcing the liquids to mix in the nanometer scale 
(Panagiotou et al., 2007).  
                                                                                                            Chapter 5 – Results and Discussion 
 
38 
 
 
Figure 5.2 Mean Circular Equivalent Diameter, in 𝜇m, obtained through image analysis for all the formulations 
(Blue - Covaris Formulations, Green – Reactor Formulations, Orange – PureNano formulations). Note that the 
bars represent the standard deviation between the 300 particles that were measured. 
 
5.3.  Drug’s Solid State in the Spray-Dried Co-Precipitated Powders 
 
In figure 5.3 the powder diffractograms corresponding to the raw materials (polymer and pure model 
drug) are presented as well as trials #3, #4, #7 and #8 performed for each technology and amorphous 
powder of the model drug produced by SD. 
The XRPD analysis was performed to evaluate the presence of crystalline drug material in the 
formulations produced. Thus, regarding the drug’s solid state of the formulations, there were differences 
in the spray dried co-precipitated powders produced using different technologies. When overlapping the 
drug substance and formulations (7 and 8) diffractograms, a single polymorphic form of the model drug 
was observed (coincidence peaks’ characteristics from pure model drug in all trials). So, no polymorphic 
changes occurred during the co-precipitation and SD processes. 
The first conclusion is that trials #3C, #4C, #3R, #4R and #4P are in the amorphous form, as no 
characteristic crystalline diffraction peaks of the model drug appear, it can only be found a hallow 
characteristic of the amorphous form. Secondly, it can be concluded that all powders generated in trials 
#7 and #8 contain crystalline API, meaning that crystalline solid dispersions were formed in these cases. 
Regardless of the technology applied, these are the trials with the higher feed solids concentration 
(12%). This can be justified by the fact that the initial solution is nearest the supersaturated state for the 
trials that present higher feed solids concentration when compared to the lower ones (#3 and #4). This 
would increase the level of supersaturation, and as this parameter is the driving force of the precipitation 
process, result in a major amount of crystalline material that precipitates, or in other words, less material 
delays in solution to precipitate, probably in SD process under amorphous form.  
It is worth mentioning that for trial #3P crystalline API was also detected in the corresponding XRPD 
diffractogram: nevertheless, the amount present, if one considers the intensity of the characteristic peak 
of the API (localized at about 10.3º 2𝜃) as reference, is much smaller than the one of #7 and #8 trials.  
The diffractograms of formulations #7 and #8 show a significant lower peaks intensity when compared 
to the pure drug substance or even to the blend drug:polymer, meaning that the integrity of the raw 
materials was not maintained. Nevertheless, it is important to highlight that for formulations #7C and 
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#8C, the peak is smaller than for #7R and 8R, meaning that more amorphous drug is present on the 
first ones (data below will prove this). Thus, and as already mentioned, the formation of amorphous drug 
material was promoted, possibly when subject to SD, as a result of the amount of dissolved material 
that remains in solution (Pietilainen, 2013). This event may be due to the fact that the antisolvent flow 
rate was higher than the solution flow rate for all the technologies, may provide a sporadic uptake of 
saturated solution (Brown et al., 2015).  
 
Figure 5.3 Powder diffractograms correspondent to trials #3, #4 #7 and #8 produced by the three technologies 
used and also the raw materials and amorphous drug. Note that all the diffractograms were normalized, dividing 
the intensity in all the points by the maximum intensity verified in each sample. Besides that, a constant was 
added at each diffractogram in order to separate them, so the units are arbitrary.  
 
In order to quantify the percentage of crystalline material present in each formulation produced, and to 
conclude which sample presents a higher percentage of crystallinity, it was thought to use the DSC 
technique. This technique not only is important to evaluate endothermic and exothermic events and to 
determine the temperatures at which those occur, as mentioned in 4.2.10, but also, according to Gill et 
al. 2010, allows the estimation of the percentage of crystallinity, without being mandatory the preparation 
of a calibration curve, by using the following equation: 
 
% 𝐶𝑟𝑦𝑠𝑡𝑎𝑙𝑙𝑖𝑛𝑖𝑡𝑦 = ∆𝐻𝑓 −
∆𝐻𝑐
∆𝐻𝑓
𝑃𝑢𝑟𝑒 ×  𝑚 
Equation 5.1 
where ∆𝐻𝑓 refers to the heat of fusion of the sample, ∆𝐻𝑐 the heat of crystallization of the sample, ∆𝐻𝑓
𝑃𝑢𝑟𝑒 
the heat of fusion of pure crystalline sample and m is the weight of the sample. 
As the equation shows, to determine the percentage of crystallinity it is necessary to use the DSC 
thermograms with a well-defined peaks corresponding to recrystallization and fusion. However, the DSC 
thermograms present in figure 5.4 do not reveal the crystallization peak and the melting attributed to the 
API is not resolved from the endothermic transition assigned to water release from the API crystalline 
structure. Based on this, the approach proposed to estimate crystallinity cannot be applied in this case. 
The DSC curves (Figure 5.4 (a) and (b)) show that at 50-90 ºC there is a broad endothermic peak that 
can be attributed to bulk water release. At higher temperatures (110-140ºC), another large endothermic 
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transition is clearly visible both on the API on the physical mixture and on formulations #7R and #8R 
(Figure 5.4 (a)). This is due to the release of the water from the crystalline structure of the API; at this 
stage, the anhydrous form of the model drug is obtained. With increasing temperature, this will melt 
which is given by a small endothermic transition observed at above 150ºC. For the amorphous 
formulations (#3 and #4) and for the ones with lower crystallinity (e.g. #7C, #8C) a step change in the 
baseline is verified at about 130ºC (Figure 5.4 (b)); this is most probably attributed to the glass transition 
temperature of the amorphous material. In fact, the amorphous API has a glass transition temperature, 
as determined by mDSC, of about 134ºC (figure 5.5). In all cases, at higher temperatures, above 200 
ºC, the degradation of the drug occurs which is characterized by an exothermic event. 
 
    
 Figure 5.4 DSC thermograms corresponding to (a) crystalline trials #7R, #8, pure drug substance and 
physical mixture and (b) amorphous trials #3, #4 for all technologies and #7 and #8 for Covaris and PureNano 
technologies. 
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Figure 5.5 Reversible heat flow curve of mDSC thermogram corresponding to pure drug substance in the 
amorphous state. 
 
After reaching the conclusion that it is not possible to obtain an estimative of the amount of crystalline 
material present in the samples by the DSC technique, an alternative approach was used by XRPD. 
This approach was based on the comparisons between the net height of the characteristic API peak 
localized at 2𝜃 = 10,3° of the physical mixture and of the formulations which reveal some content in 
crystalline material in XRPD analyses, i.e., #7 and #8 trials. In table 5.1., it is shown the net heights of 
the different formulations measured by Data Viewer software and the respective percentage of 
crystallinity, using the physical blend as the standard sample. 
 
Table 5.1 Net heights of the different formulations measured by Data Viewer software and the respective 
percentage of crystallinity. 
 Net Height % of Crystallinity 
#7R 5985.4 41.6 
#8R 2798.2 19.4 
#7C 1827.5 12.7 
#8C 1276.4 8.9 
#7P 2566.9 17.8 
#8P 6061.3 42.1 
Physical Mixture 14395.5 100 
 
Although this approach only provides a rough estimation of the crystallinity percentage in each sample, 
an ascending ranking order related with the amount of crystalline material could be established: 8C < 
7C < 7P < 8R < 7R < 8P. Analyzing these results, no valid explanation can be proposed as according 
to the differences in the formulations and production processes used no correlation or logic trend can 
be drawn.  
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5.4.  Determination of Drug Content in the Formulations  
 
Figure 5.6 presents the drug content for all the formulations corresponding to trials #3, #4, #7 and #8 of 
the DoE performed using the three different technologies. The final values of the drug content were 
corrected according to the TGA analysis, whose purpose was to determine the weight loss related with 
residual solvents and water. 
As far as the information presented in the figure is concerned, it is possible to conclude that, in all cases, 
the drug content of the formulations produced is lower than the theoretical value (60 % wt.). Considering 
the conventional and the Covaris technologies, identical values are obtained within each group, being 
the only exception in Covaris technology for trial #7C, that presents even a lower drug content, i.e 
approximately 10 % less when compared to the other trials produced by the same technology. PureNano 
technology presents large fluctuations of drug contents, particularly noted in trials 7 and 8.  
In order to understand if the cause for this low drug content could be related with the UPLC method 
used, in particular with the correspondent sample preparation, pure drug samples diluted in MeOH were 
injected with certain known concentrations using the UPLC, and the values acquired were in accordance 
with the expectation (i.e. 98%), moreover, good agreement was obtained for different sample 
preparations (D-checks between 95-105 %). So the only possible explanation for the lower drug content 
(about 10 % less than the theoretical value), could be related with some problems verified in SD process, 
namely the clogging of the nozzle, resulting in the loss of some material, that deposits in the chamber 
walls as a result of pulse actions to try to unclog the nozzle. This is also confirmed by the low yield rates 
obtained in SD, especially in formulations 7 and 8. A suggestion to address this problem is the use of 
an orifice with a wider diameter (2.2 mm), avoiding or minimizing the clogging of the nozzle. 
Nevertheless, this change would have an influence on the final particle size of the spray-dried co-
precipitated powders. 
When comparing the drug content of the formulations produced with the conventional approach and 
Covaris Technology, it is possible to conclude that a higher drug content is obtained when the latter 
technology is used. Although the yield of the Covaris process cannot be calculated since it is followed 
by an isolation step (SD), the fact that the process elapsed at continuous controlled temperature may 
provide higher recovery yields and make possible to preserve the fidelity of the sample (Covaris, 2016). 
 
Figure 5.6 Drug Content present in the formulations produced through the different technologies used (Blue – 
Covaris Formulations, Green – Reactor Formulations, Orange – PureNano formulations). Note that the bars 
represent the standard deviation from the drug content studies performed in duplicate. 
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Figure 5.7, presents the TGA analysis performed for all the formulations produced through the three 
technologies used in this thesis. TGA analysis was performed with the main purpose of studying the 
weight loss attributed to water and residual solvents, revealing consistent results, in what concerns 
thermal sample behavior, with the DSC analysis.  
In the beginning of the weight loss curve (%) there isn’t a well-established and defined plateau, in 
comparison to the pure model drug curve. Indeed, the formulations soon begin to lose weight when 
subjected to temperatures slightly higher than the room temperature (first down ramp in the curve), 
which means that the formulation contains, as expected, bulk water that is coming out with increasing 
temperature. Then, a small-weight loss occurs possibly because of the presence of residual solvents 
used in the process (DMF and water); this is represented by the second down ramp observed in the 
formulations TGA curves. Lastly, the down ramp that follows at about 140-170 ºC, corresponds to the 
water from the API crystalline structure (monohydrate). In fact, this weight loss is occurring at the same 
temperature as for the pure API for which the % weigh loss is of 4.13 %, which is in agreement with the 
theoretical value for the monohydrate (3.6 - 4.6 %). At higher temperatures (>200 ºC), and in agreement 
with the DSC, melting, followed by decomposition, occurs. 
 
Figure 5.7 TGA thermograms corresponding to all the formulations produced using different technologies, as well 
as the pure model drug thermogram. 
 
In table 5.2., the total weight loss of water obtained for all the formulations is presented. The values 
listed in the table are very similar among the different technologies used, however the aforementioned 
values are extremely high when compared to the theoretic value of water content that the model drug 
should present, 3.6 to 4.6 % wt. defined by the European Pharmacopeia 5.0. The value of water content 
in pure model drug, as determined by the TGA experiment, is 4.13 % wt., which is in the range already 
mentioned. As the formulations were produced using water as the antisolvent and contained also a 
polymeric matrix, with the ability to swell incorporating water molecules, the values discrepancy between 
the theoretical total weight loss and the values obtained was predictable. Like this, the drying conditions 
in the isolation step are fundamental, so an optimization of the conditions can improve the mentioned 
difference in the values of weight loss. 
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Table 5.2 Total weight loss (% wt.) obtained for all the formulations produced, through TGA analysis. 
 Stirred Reactor (#R) Covaris (#C) PureNano (#P) 
#3 11.18  9.33 11.08 
#4 10.91 9.51 7.68 
#7 7.91 17.55 7.81 
#8 9.63 9.71 8.30 
  
As previously stated, these values were used to calculate the drug content of the formulations presented 
in figure 5.6.  
 
5.5.  In vitro Dissolution Studies 
 
In figure 5.8 the results for all the formulations produced using three different technologies are shown, 
within the first 10 min of the first approach of in vitro dissolution studies in simulated salivary fluid 
medium. The time-points were selected considering the residence time of drugs in the oral cavity, which 
is about 5-10 min (Bartlett and van der Voort Maarschalk, 2012).   
A result expected is the fact that the amorphous API dissolves more than the crystalline API, since the 
first polymorphic form represents the best solubility case, which according to Noyes-Whitney equation 
(Noyes and Whitney, 1897) translates in a higher dissolution rate and consequently better bioavailability. 
Nevertheless, the difference in the amount of drug release between amorphous and crystalline API was 
not so significant as expected, since it combines the amorphous form (promoting better dissolution 
rates) with smaller size particles (produced by SD), supposedly further increasing the dissolution rate. 
However, investigations with pure nanocrystals, i.e. 100 % API with no use of stabilizer or polymers, 
that aims to study the effect that the particle size can have in dissolution rate haven’t been reported with 
the desired frequency (Deng et al., 2012). For that reason, for many drugs there is a gap of the true 
impact that the particle size can have on the dissolution rate. In the situation mentioned above, we 
should keep in mind that the amorphous drug was produced by spray drying technology starting from a 
solution and according to what was mentioned in subchapter 5.1, the spray dried powder would be 
inflated, most likely resulting in a lower bulk density (when compared to the raw material, pure API), 
occasioning subsequently an increasing in the dissolution rate.  
The API by itself present a higher drug release when compared with some of the formulations, which 
was expected since the polymer coating plays an important role in what concerns the reduction of the 
drug release, as reported by Hoang Thi et al., 2012. Additionally, considering that the pure drug is 100 
% crystalline and in some cases the formulations are fully amorphous, and according to the reasons 
stated previously, some formulations may present a higher dissolution rate than would be expected if 
the polymorphic form was the intended.  
Thus and concluding, the polymorphic form (amorphous or crystalline) seems not to have a significant 
impact on the dissolution profiles of the formulations. Hence, it was not possible to establish a correlation 
between the dissolution profiles and the amount of crystalline material roughly estimated in XRPD 
analysis, in subchapter 5.1. 
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According to the general criteria announced before, in subchapter 3.4, the FIP/AAPS guidelines suggest 
that in order to achieve taste masking, the API has to dissolve usually less or equal to 10 % in the first 
5 min of dissolution. Regarding the results displayed in the following figure, this condition was verified 
for the commercial product and trials #7R, #8R, #4C, #3P, #4P, #7P and #8C. Nevertheless, it is 
important to note that the dosage form of the commercial product is not powder but a dispersible tablet, 
that suffers compression, and beyond that, the tablet is coated with enteric excipients. As mentioned in 
literature, the dissolution profile can be clearly affected by the oral dosage form, excipients used (Habib 
et al., 2000), compression forces (Ghadiyali et al., 2013), as well as the particle size of the result powder 
(Habib et al., 2000), making it necessary to be careful when comparing with the formulations produced.  
The formulation with the lower drug release in the first 5 minutes was trial #7P, releasing about 3.97 % 
of the drug. There are other promising formulations, namely #4C, #3P, #4P, however, the API in these 
formulations is in the amorphous form, which is not the target polymorphic form. 
 
Figure 5.8 Dissolution profiles corresponding to all the formulations produced (Blue – Covaris Formulations, 
Green – Reactor Formulations, Orange – PureNano formulations) and also the amorphous powder produced 
through SD, raw material (crystalline model drug) and a commercial product. Note that the bars represent the 
standard deviation from the performed dissolution profiles performed in duplicate. 
 
As previously described, a second approach, the pH shift one, was also applied to evaluate the 
dissolution profile of the formulations. 
The drug release profiles, using the pH shift approach as a function of dissolution time of the trials #7R, 
#8C and #7P in comparison to the commercial triturated and not triturated product, i.e., as a dispersible 
and coated tablet, are shown in figure 5.9. Considering that the model drug is partially absorbed in the 
stomach and upper gastrointestinal tract (O'Connor, 2004), two dissolutions medium were selected to 
mimic these conditions. The first dissolution medium selected, HCl 0.1 N, intended to mimic the stomach 
content. To mimic the gastrointestinal tract, FeSSIF was selected, attending that the absorption of the 
model drug is improved with food, i.e., after the ingestion of food (O'Connor, 2004).  
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Figure 5.9 Dissolution profiles corresponding to the pH shift approach tested in the formulations #7R (green line, 
lozenges), #8C (blue line, triangles), #7P (orange line, cross) and commercial triturated (black line, quadrates) 
and not triturated (black line, circle) product. The vertical dashed line at the 30 min time point corresponds to the 
pH-shift. The bars correspond to the standard deviation from duplicates experiments. 
 
The pH change performed at 30 minutes for all the formulations tested, does not impact the solubility of 
the drug, or in other words, the solubility is independent of pH.  
These dissolution profiles seem to indicate that once the drug reaches the stomach, it dissolves very 
well and maintains its solubility when directed towards the intestine. This is a good sign since the drug 
is absorbed in the final stage of the stomach and in the upper intestine.  
Generally, a drug release of between 60 to 80 % was obtained for all the formulations tested. For 
benchmarking purposes, the dissolution profiles of the promising formulations were compared with the 
one acquired for the commercial product triturated and not triturated, showing similar dissolution profiles, 
in the stomach and the intestine. Thus, the pH shift dissolution method allows to conclude that the 
formulations do not seem to have been impacted by any of the co-precipitation processes used. 
In this approach, the commercial product was tested as a coated and dispersible tablet (not triturated) 
but also as a powder (triturated), in order to study the differences in the dissolution profile. The results 
show that the burst release in the first 15 minutes was significantly higher as a powder rather than as a 
tablet. This result was expected since the enteric polymer coating film was destroyed with the triturate 
process, for that reason the drug is faster released in the dissolution medium and, subsequently a higher 
burst release was obtained in this case. 
Throughout the experiments conducted, it was observed that apparatus 2 is not the most suitable 
dissolution apparatus to use, when the dosage form is powder. The powders fluctuate, and when the 
samples are taken, material is removed from the medium, generating experimental errors. Thus, the 
utilization of apparatus 4, a Flow-Through Cell Apparatus, would be important to minimize and avoid the 
propagation of errors.  
In order to study all the trajectory of the drug release in the human body, beginning in the mouth, 
stomach and finally the intestine, it would be very interesting to develop new methods that can mimic 
these pH changes, volumes and dissolution media in a continuous mode (Fotaki, 2011). In the future, 
the utilization of apparatus 4 for this effect should be studied and evaluated.  
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5.6.  Determination of Encapsulation Efficiency 
 
5.6.1. SEM-EDS Analysis 
 
The purpose of EDS analysis was to assess the encapsulation, relating it with the taste masking 
properties. According to the molecular structure of API and polymer, the only differentiator element 
between both is nitrogen and thus, this element was used in this analysis. The concept used is very 
simple: if the nitrogen is detected by an EDS microscope in lower percentage when compared with the 
standard sample (pure drug substance), it is possible to conclude that the encapsulation is efficient and 
probably good taste masking properties will be obtained. 
Figure 5.10 shows the encapsulation efficiency determined through EDS analysis for the trials #7 and 
#8 of each one of the technologies used (crystalline samples). In table 5.3 the detected values of 
nitrogen by EDS microscope are shown, as well as the associated error to this detection.  
A first indication that something wasn’t right in this technique, was the nitrogen weight percentage 
detected by EDS microscope for a pure API sample, 13.8 % (table 5.3). This value is very inflated, since 
the theoretical value of percentage by weight of nitrogen is about 6.4 %. As the EDS microscope does 
not detect hydrogen, this calculated theoretical value of percentage by weight of nitrogen was corrected, 
becoming 5.8 %.  
The results were consistent regarding the detected values of nitrogen between the pure API sample and 
the first point analyzed through EDS microscope in the physical mixture (blend 60:40 % wt. of 
API:Polymer), confirming the presence of API in this mixture. 
In the second point of the physical mixture analyzed by EDS microscope, the negative nitrogen detected 
value of -11 % has no physical meaning. Thus, the interpretation of these results should be considered 
carefully and cannot be taken literally. Accordingly, the only conclusion possible to draw is that no 
nitrogen could be detected at this point of the sample, which combined with the SEM micrographs, i.e., 
analysis of particles morphology, allows to infer that only the polymer is present.  
Another indication of the variability and error of this technique is the fact that, in the majority of the 
analysis, the standard deviation of the nitrogen element was much higher when compared to the 
detected value by SEM-EDS microscope. Thus, it is not possible to conclude if there is nitrogen or not. 
As figure 5.10 and table 5.3 shows, for the trials where the value of nitrogen detected was higher than 
the nitrogen detected in the pure API sample (#8R, #7P and #8P), the EE was negative. As mentioned 
before this does not make any physical sense, indeed, the only conclusion that can be made in this case 
is that the entrapment of the drug within the polymer was not accomplished for those trials.  
Knowing the information that EDS has a limitation in the detection of light elements with atomic weight 
inferior than 11 (Australian Microscopy and Microanalysis Research Facility, 2014)), everything points 
to the fact that this technique is not suitable to provide information about the encapsulation efficiency, 
and consequently taste making properties, for this particular drug substance.  
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Figure 5.10 Encapsulation Efficiency corresponding to trials #7R, #8R and #7C, #8C determined through the 
nitrogen detected values by EDS microscope.  
 
Table 5.3 Values detected of nitrogen by EDS microscope and associated error to this detection, both in weight 
percentage.  
 N Detected (weight %) 𝝈 (weight %) 
#7R 0.9 19.7 
#8R 21.9 8.4 
#7C 9.2 14.6 
#8C 6.8 19.4 
#7P 14.6 7.0 
#8P 16.1 5.7 
Physical Mixture  
14.4 5.75 
-11.96 23.24 
Pure API 13.8 6.93 
 
It is important to note that the duration of the electron beam in the samples was not always the same, 
as well as the number of counts in all the trials, this can impact the precision of the measurement of 
nitrogen value present in the samples. 
The large depth analysis characteristic from EDS, that can reach to a few 𝜇𝑚 (Ferraria, 2002; van der 
Heide, 2012), is a huge limitation. And, due to the small particle size of the samples, the electron beam 
may penetrate the entire particle, giving information of the overall composition of the particle instead of 
its surface composition. For that reason, an alternative that would allow the evaluation of the 
encapsulation efficiency had to be found, and this was to perform XPS analysis.  
 
5.6.2. XPS Analysis 
 
This technique allows to obtain a detailed chemistry composition of the surface with a depth analysis 
that can reach up to 10 nm-outermost layer composition of particles, in certain cases giving the 
possibility of characterizing the first 10 to 20 atomic layers of the irradiated surface (Ferraria, 2002). 
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Besides that, this technique also consents the study of the oxidation numbers of the elements identified 
in the sample.  
In table 5.4, the experimental atomic concentrations (%) and atomic ratios for the formulations as well 
as for pure drug and physical mixture can be seen and, for comparison purposes, the nominal atomic 
concentrations and ratios are also included. 
 
Table 5.4 Experimental and theoretical atomic concentrations (%) and atomic ratios of the formulations #7R, #7P, 
#8C and standards of pure drug and physical mixture. 
 
Experimental Values Theoretical Values 
Pure 
Drug 
Physical 
Mixture 
# 7R #8C #7P 
Pure 
Drug 
Physical 
Mixture 
C 66.0 65.0 65.8 64.7 65.9 66.7 68.0 
O 27.3 31.9 31.2 31.2 31.2 27.3 28.4 
N 6.7 3.1 3.0 4.2 3.0 6.1 3.7 
Ratio O/C 0.41 0.49 0.47 0.48 0.47 0.41 0.42 
Ratio N/C 0.10 0.05 0.05 0.06 0.04 0.09 0.05 
Ratio N/Ccarboxyl - 0.42 0.37 0.67 0.34 - 0.62 
EE (%) - - 55 37 55 - - 
 
The value of nitrogen for the pure drug standard sample (6.7 %) is comparable with the theoretical value 
(6.1 %). This is also confirmed by the match between the experimental ratio (0.10) between nitrogen 
and carbon and the theoretical value (0.09). Nevertheless, this ratio quantifies all the carbon atoms that 
exist in the system, including the carbons from aliphatic contamination (from the double sheet glue). 
Thus, this quantification might lead to inconclusive comparisons.  
The value of nitrogen detected in the physical mixture (a blend of polymer-drug in the proportion used 
to produce the different formulations), is only slightly smaller (3.1 %) when compared to the theoretical 
value considering a homogeneous mixture, without stratification (3.7 %).  
The O/C ratio does not provide considerable information on the system analyzed, since similar values 
were obtained and no substantial differences were noted in the atomic concentrations of oxygen and 
carbon.  
The ratio that allows us to extract more information is the ratio between nitrogen and carboxyl groups. 
In fact, this ratio can provide insights to the distribution profile of the model drug and polymer in the 
sample, since the nitrogen atom only exists in the model drug and carboxyl and ester groups only exist 
in the polymer.  
The experimental value of the physical mixture is lower than the theoretical value (a homogeneous 
mixture, with no stratification). So apparently, this result is compatible with some microencapsulation of 
the model drug by the polymer, in the physical mixture. However, it is important not to forget that the 
particle sizes of polymer and drug are significantly different and this blend was not processed. Thus, it 
is not about a microencapsulation process, but a stratification phenomenon of the polymer at the surface 
of the model drug molecules. The occurrence of this phenomena can be confirmed comparing the SEM 
micrographs for the physical mixture and pure drug (figure B.1 and B.2, Supplementary Information). 
For this reason, less nitrogen was found (from the pure drug) and more carboxyl groups were detected 
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(from the polymer). Thus, this experimental result shouldn’t be used for comparison purpose and to 
determine the EE, since it’s a source of errors propagation. 
The samples #7R and #7P are the ones that apparently present a more efficient encapsulation, since 
the ratios N/Ccarboxyl, 0.37 and 0.34 respectively, are lower than the theoretical value (0.62). On the other 
hand, the sample #8C appears to be segregated at the surface of the polymer, since the ratio N/Ccarboxyl 
is higher (0.67) when compared with the theoretical value (0.62).  However, the EE was determined 
using the same formula applied in EDS analysis, i.e., in which the standard sample was the pure drug. 
If stablishing an ascending ranking order for the formulations in terms of EE, it would be: 8C < 7R ≈ 7P. 
But undoubtedly, #7P is the best formulation since when the ratios between nitrogen and carboxyl 
groups are compared with trial #7R, the first one is slightly lower.  
The results of EE are well correlated with the dissolution studies, and thus dissolution studies data can 
be a good indication of EE. Nevertheless, as clearly shown, if the aim is to determine or quantify the 
drug entrapped on the polymeric matrix, the use of XPS analysis is preferred instead of EDS analysis. 
Furthermore, this technique can be an important and useful tool for the systems that don’t have any 
distinct element in their molecular structures, but only differ in functional groups, as explained by Hoang 
Thi et al., 2012.  
Figure 5.11, shows XPS region (a) C 1s and (b) N 1s for the different formulations tested. N 1s was 
fitted using two peaks with different binding energies. The peak that is centered at the lower binding 
energy (~ 399.6 ± 0.1 eV) corresponds to the presence of pure model drug amide ((C=O)-NH2) and 
amine groups (N-CH3), the other peak at the higher binding energy (~402.1 eV) is assigned to 
protonated nitrogen (N+).  The C 1s region includes the aliphatic C-C and C-H (peak at 285 eV, which 
also includes aromatic carbons), C-N at 286 eV from tertiary amines, C-O and C=O which, on average, 
are 1.4 eV apart from each other, included in a single peak centered at 287 eV. At 289.4 eV is assigned 
the contributions from O-C=O and COOH. 
Comparing the spectrums of C 1s regions among the different formulations, it seems that only the model 
drug exhibits peaks at 290.8± 0.2 eV, assigned to the 𝜋 − 𝜋∗ transitions typical from systems with 
delocalized electrons, as the benzene rings of the model drug. So, apparently, no model drug is present 
at the surface of the spray-dried particles. Nevertheless, these electronic transitions may be present in 
the formulations but covered by other interactions, since for values near that binding energy, there is 
peak at 289.4 eV, that appears in all the formulations, assigned to –O–C=O and –COOH, characteristic 
from polymer. 
Contemplating the N 1s regions of the produced formulations and also the ratio between protonated 
nitrogen and total nitrogen, in table 5.5, the formulation that apparently present a higher relative amount 
in protonated nitrogen is #7R, followed by #8C and finally #7P. The expected result would be formulation 
#8C presenting a higher relative amount in N+, since this formulation was produced with a higher SAS 
volume ratio (1:10) when compared to the other formulations produced with 1:6 of SAS volume ratio. 
So, in the case of the #8C trial, there is more quantity of acidic medium, and since the model drug is a 
weak base it would be expected that protonation is favored and therefore a higher amount of N+ should 
be predictable when compared to the other formulations. However, these relative amounts don’t 
represent the absolute value in protonated nitrogen and although the #7R trial was produced with less 
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amount of antisolvent, the use of a stronger acid (lower pH value) may result in a higher level of 
protonation, leading to a higher relative amount in N+. Therefore, the use of high SAS volume ratio and 
strong acids seem to compromise the EE provided. Moreover, attending the standard deviation in 
dissolution profiles in SSF and that the SAS volume ratio can impact the relative amount in N+, if trial 
#7C was evaluated, it should demonstrate a high EE when compared to trial #8C.  
If the spectra of formulation #7P is compared with the other formulations and even with the standard 
samples (pure model drug and physical mixture), it can be seen that the two peaks, which comprise the 
spectra, seem to be less distinguishable or in other words, the peak assigned to amide and tertiary 
amines in N 1s of sample 7P is slightly shifted to higher binding energies, as can be seen in table 5.6. 
So, a modification on the nitrogen structure occurred as a consequence or an effect of an efficient 
encapsulation, and thus, there are more nitrogen atoms available to stablish hydrogen bonds, acting 
like a donor of its isolated par.  
 
Table 5.5 Ratio between protonated nitrogen and total nitrogen calculated for all the formulations. 
 Ratio N+/Ntotal 
Pure Drug 0.37 
Physical Mixture 0.40 
# 7R 0.42 
# 8C 0.32 
# 7P 0.29 
  
Table 5.6 Binding energies, in eV, of N 1s fitted peaks. 
 Assignments Pure Drug Physical Mixture #7R #7P #8C 
N1 
-(C=O)-NH2; 
N-CH3 
399.6 399.5 399.5 399.9 399.7 
N2 N+ 402.3 402.1 402.1 402.1 402.3 
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Figure 5.11 XPS (a) C 1s regions and (b) N 1s regions of the different formulations tested: pure drug, physical 
mixture, #7R, #7P and #8C (from the bottom to the top). Note that a constant was added to separate the 
spectrums. 
 
 
 
 
 
 
 
(a) (b) 
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6. Conclusions and Future Work 
  
Taste masking is critical in the development of solid oral dosage forms since it is related to patient 
compliance, especially for pediatric populations. For that reason, the development of new processes 
that can assure the achievement of taste masking is important. For this effect, and considering the 
several approaches that already exist, microencapsulation was selected, using different co-precipitation 
processes to produce a suspension followed by an isolation step by spray drying.  
Considering the particles morphology, similar micrographs were obtained among the different 
technologies used to produce the formulations. Particles obtained were spherical, which was expected 
due to the isolation step selected. The SEM images reveals no API particles at the surface of the 
spherical ones, with the exception of trial #4C, where probably the EE and taste masking properties 
could have been compromised. The presence of agglomerate structures was verified in some of the 
micrographs, due to the residual solubility that will always exist in the suspension, used as a starting 
point on SD process. 
The particle size indicates a narrow PSD and smaller particles for Covaris, followed by Purenano and 
finally the conventional approach, mainly because of the elevated mixing capacity promoted by the first 
two technologies. 
The results suggest that the formulations were taste masked using any of the processes disclosed in 
this work.  Nevertheless, the encapsulation of the model drug by PureNano technology was the best 
approach when compared to Covaris technology as welll as the conventional approach. Thus, the best 
formulation was #7P, presenting a slower drug release in SSF medium, which is in accordance with the 
high particle size when compared to other formulations, and also the best results in terms of EE by XPS 
analysis.  
The fact that PureNano seems to be the best technologies in order to achieve taste masking when 
compared to the conventional approach, can be related with a high mixing rate, resulting in a comparable 
time between NPs assembly and solvent diffusion, and consequently, a major amount of drug can be 
encapsulated within the carrier (Sarghini, 2015). 
Higher values of EE were expected, namely in MRT, since several studies reported encapsulation 
efficiency values in order of 95 % or greater, due to the generation of single droplets during 
microparticles formation, where no drug is lost in the droplets (Sarghini, 2015). Nonetheless, it is 
important to highlight that following the co-precipitation process, an isolation step was performed and 
the problems already identified in the process, namely the clogging of the nozzle, can have an impact 
on EE. For that reason, the orifice of the nozzle should be altered for the bigger size. So, an optimization 
on the SD process and a compromise between several parameters is necessary. 
In this work, the formulation variables studied were the drug load, SAS volume ratio and feed solids 
concentration. However, there are other variables that can impact the CQAs of the final product. In future 
studies, other formulation variables should be considered, as for example the type of polymer used and 
the addition of surfactants, as well as other process variables, such as flow rate and mixing capacity. 
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Considering that in this work only an intermediate product was obtained, it would be important to produce 
a final product (e.g. capsule or tablet) and re-evaluate the characteristics related with taste masking, in 
order to analyze if the process mentioned has any impact in taste masking properties.  
Regarding EE results, it was concluded that EDS analysis had many limitations and was not appropriate 
for this particular model drug, contrary to XPS analysis. It was also possible to conclude that the 
dissolution studies provide good indications of EE, that are well correlated with XPS analysis, being the 
best formulations in terms of taste masking properties: 7P > 7R > 8C. Further works should be 
conducted to study and develop new methods/apparatus that are able to mimic the oral cavity, in terms 
of volumes, medium and time-points (tighter time-points in the first 5 minutes of dissolution).  
The criteria established by FIP/AAPS regarding the accomplishment of taste masking is very 
generalized and does not take into consideration the model drug and its bitterness threshold 
concentration. And although the bitterness threshold concentration of the model drug used is not 
reported in literature, further works should be performed in order to determine this value and have the 
possibility of comparing the drug’s release in the formulations in the first minutes with the bitterness 
threshold concentration, so that it is possible to conclude about the success of taste masking the bitter 
taste of the drug. 
It would be also very interesting to develop new dissolution methods for this particular drug that can 
mimic its complete trajectory in the human body, from the oral cavity, passing through the stomach to 
the intestine tract, where the drug is absorbed, in order to study the success of encapsulation but also 
the drug’s release in the human body. For this purpose, as mentioned before, apparatus 4 should be 
used.  
Concerning the in-vitro data obtained, it would be very interesting to correlate it with in-vivo studies, 
namely in panel human tests or animal preference tests. But attending the ethical concerns of the 
experiments mentioned, it would certainly be more appropriate to test other types of approaches, for 
example electronic sensor methods, in particular an electronic tongue.  
In conclusion, all the objectives proposed for this work were successfully achieved, namely concerning 
the benchmarking of the different co-precipitation techniques used, and their impact in the CQAs and 
mainly, in EE and subsequently taste masking properties.  
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Supplementary Information 
 
A. In-vitro Dissolution Studies 
 
In figure A.1, the calibration curve performed in UPLC method is shown, in order to quantify the model 
drug in the formulations and to assure that the linearity conditions were verified. 
 
Figure A.1 Calibration curve of the model drug in methanol, with concentrations ranging from 20 to 200 𝜇g/mL. 
 
In order to obtain the final drug release in every time-point, the recovery area (quantified through the 
use of a single-point external standard of pure drug substance in MeOH - 80 μg/mL) was considered, 
the mass existing in the volume present in the vessel and also the replace of the medium. 
Thus, the recovery area was calculated as the following formula suggest: 
 
𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑦 𝐴𝑟𝑒𝑎 =
𝑃𝑒𝑎𝑘 𝐴𝑟𝑒𝑎 𝑜𝑓 𝑡ℎ𝑒 𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑆𝑎𝑚𝑝𝑙𝑒
𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑡ℎ𝑒 𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑆𝑎𝑚𝑝𝑙𝑒
×
𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑡ℎ𝑒 𝑆𝑎𝑚𝑝𝑙𝑒
𝑃𝑒𝑎𝑘 𝐴𝑟𝑒𝑎 𝑜𝑓 𝑡ℎ𝑒 𝑆𝑎𝑚𝑝𝑙𝑒
× 100 
 
Equation A.1 
 
where the concentration of the sample was corrected according to the dilution performed, through the 
use of the dilution factor, so that the concentration ranges between the values of the calibration curve. 
The value obtained for each one of the time-points was multiplied by the volume present in the vessel 
and also by the replace volume medium, individually.  
The final drug release was obtained by summing the mass present in the volume of the vessel in that 
time-point and the mass of the reposition volume media in the previous time-point.  
The experiments were performed in duplicated, so in order to obtain the final drug release an average 
was done and the standard deviations were calculated.  
From table A.1 to A.15, the obtained results for the first dissolution method applied are explicit, 
considering the calculations previously explained.  
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Table A.1 Final drug release and respective standard deviation (𝝈) correspondent to formulation #3R, in SSF 
dissolution media. 
n=1 
Recovery 
Area 
Mass in 10 
mL 
Mass in 2 
mL 
Final Mass 
 
0 min 0 0 0 0 
5 min 1.60 15.97 3.19 15.97 
Time 
(min) 
Average 
Mass 
𝝈 
10 min 1.64 16.39 3.28 19.58 0 0 0 
n=2 
Recovery 
Area 
Mass in 10 
mL 
Mass in 2 
mL 
Final Mass 5 12.73 4.58 
0 min 0 0 0 0 10 16.37 4.54 
5 min 0.95 9.49 1.90 9.49 
 
10 min 1.13 11.26 2.25 13.16 
 
 
 Table A.2 Final drug release and respective standard deviation (𝝈) correspondent to formulation #4R, in SSF 
dissolution media. 
n=1 
Recovery 
Area 
Mass in 10 
mL 
Mass in 2 
mL 
Final Mass 
 
0 min 0 0 0 0 
5 min 3.53 35.30 7.06 35.30 
Time 
(min) 
Average 
Mass 
𝝈 
10 min 2.01 20.05 4.01 27.11 0 0 0 
n=2 
Recovery 
Area 
Mass in 10 
mL 
Mass in 2 
mL 
Final Mass 5 22.24 18.47 
0 min 0 0 0 0 10 24.99 3.00 
5 min 0.92 9.18 1.84 9.18 
 
10 min 2.10 21.04 4.21 22.87 
 
 
Table A.3 Final drug release and respective standard deviation (𝝈) correspondent to formulation #7R, in SSF 
dissolution media. 
n=1 
Recovery 
Area 
Mass in 10 
mL 
Mass in 2 
mL 
Final Mass 
 
0 min 0 0 0 0 
5 min 1.01 10.05 2.01 10.05 
Time 
(min) 
Average 
Mass 
𝝈 
10 min 0.99 9.90 1.98 11.91 0 0 0 
n=2 
Recovery 
Area 
Mass in 10 
mL 
Mass in 2 
mL 
Final Mass 5 8.53 2.15 
0 min 0 0 0 0 10 11.53 0.53 
5 min 0.70 7.01 1.40 7.01 
 
10 min 0.98 9.76 1.95 11.16 
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Table A.4 Final drug release and respective standard deviation (𝝈) correspondent to formulation #8R, in SSF 
dissolution media. 
n=1 Recovery 
Area 
Mass in 10 
mL 
Mass in 2 
mL 
Final Mass 
 
0 min 0 0 0 0 
5 min 1.12 11.16 2.23 11.16 
Time 
(min) 
Average 
Mass 
𝝈 
10 min 1.04 10.44 2.09 12.67 0 0 0 
n=2 
Recovery 
Area 
Mass in 10 
mL 
Mass in 2 
mL 
Final Mass 5 10.00 1.64 
0 min 0 0 0 0 10 11.39 1.80 
5 min 0.88 8.84 1.77 8.84 
 
10 min 0.83 8.35 1.67 10.12 
 
 
Table A.5 Final drug release and respective standard deviation (𝝈) correspondent to formulation #3C, in SSF 
dissolution media. 
n=1 
Recovery 
Area 
Mass in 10 
mL 
Mass in 2 
mL 
Final Mass 
 
0 min 0 0 0 0 
5 min 1.84 18.40 3.68 18.40 
Time 
(min) 
Average 
Mass 
𝝈 
10 min 2.26 22.55 4.51 26.23 0 0 0 
n=2 
Recovery 
Area 
Mass in 10 
mL 
Mass in 2 
mL 
Final Mass 5 12.61 8.20 
0 min 0 0 0 0 10 16.89 13.21 
5 min 0.68 6.81 1.36 6.81 
 
10 min 0.62 6.18 1.24 7.54 
 
 
Table A.6 Final drug release and respective standard deviation (𝝈) correspondent to formulation #4C, in SSF 
dissolution media. 
n=1 
Recovery 
Area 
Mass in 10 
mL 
Mass in 2 
mL 
Final Mass 
 
0 min 0 0 0 0 
5 min 0.99 9.90 1.98 9.90 
Time 
(min) 
Average 
Mass 
𝝈 
10 min 1.07 10.68 2.14 12.66 0 0 0 
n=2 
Recovery 
Area 
Mass in 10 
mL 
Mass in 2 
mL 
Final Mass 5 6.63 4.63 
0 min 0 0 0 0 10 10.07 3.66 
5 min 0.34 3.36 0.67 3.36 
 
10 min 0.68 6.82 1.36 7.49 
 
 
 
 
                                                                                                                          Supplementary Information 
 
72 
 
 
 
 
 
Table A.7 Final drug release and respective standard deviation (𝝈) correspondent to formulation #7C, in SSF 
dissolution media. 
 
 
n=1 
Recovery 
Area 
Mass in 10 
mL 
Mass in 2 
mL 
Final Mass 
 
0 min 0 0 0 0 
5 min 2.07 20.72 4.14 20.72 
Time 
(min) 
Average 
Mass 
𝝈 
10 min 1.41 14.15 2.83 18.29 0 0 0 
n=2 
Recovery 
Area 
Mass in 10 
mL 
Mass in 2 
mL 
Final Mass 5 13.38 10.38 
0 min 0 0 0 0 10 14.95 4.73 
5 min 0.60 6.04 1.21 6.04 
 
10 min 1.04 10.39 2.08 11.60 
 
 
Table A.8 Final drug release and respective standard deviation (𝝈) correspondent to formulation #8C, in SSF 
dissolution media. 
 
n=1 
Recovery 
Area 
Mass in 10 
mL 
Mass in 2 
mL 
Final Mass 
 
0 min 0 0 0 0 
5 min 1.25 12.54 2.51 12.54 
Time 
(min) 
Average 
Mass 
𝝈 
10 min 1.37 13.69 2.74 16.19 0 0 0 
n=2 
Recovery 
Area 
Mass in 10 
mL 
Mass in 2 
mL 
Final Mass 5 9.50 4.31 
0 min 0 0 0 0 10 13.09 4.39 
5 min 0.65 6.45 1.29 6.45 
 
10 min 0.87 8.70 1.74 9.99 
 
 
Table A.9 Final drug release and respective standard deviation (𝝈) correspondent to formulation #3P, in SSF 
dissolution media. 
 
n=1 
Recovery 
Area 
Mass in 10 
mL 
Mass in 2 
mL 
Final Mass 
 
0 min 0 0 0 0 
5 min 1.11 11.14 2.23 11.14 
Time 
(min) 
Average 
Mass 
𝝈 
10 min 1.09 10.85 2.17 13.08 0 0 0 
n=2 
Recovery 
Area 
Mass in 10 
mL 
Mass in 2 
mL 
Final Mass 5 8.22 4.12 
0 min 0 0 0 0 10 10.67 3.41 
5 min 0.53 5.31 1.06 5.31 
 
10 min 0.72 7.20 1.44 8.26 
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Table A.10 Final drug release and respective standard deviation (𝝈) correspondent to formulation #4P, in SSF 
dissolution media. 
 
 
n=1 
Recovery 
Area 
Mass in 10 
mL 
Mass in 2 
mL 
Final Mass 
 
0 min 0 0 0 0 
5 min 1.54 15.36 3.07 15.36 
Time 
(min) 
Average 
Mass 
𝝈 
10 min 1.36 13.57 2.71 16.65 0 0 0 
n=2 
Recovery 
Area 
Mass in 10 
mL 
Mass in 2 
mL 
Final Mass 5 10.29 7.18 
0 min 0 0 0 0 10 12.37 6.05 
5 min 0.52 5.21 1.04 5.21 
 
10 min 0.70 7.04 1.41 8.09 
 
 
Table A.11 Final drug release and respective standard deviation (𝝈) correspondent to formulation #7P, in SSF 
dissolution media. 
 
 
n=1 
Recovery 
Area 
Mass in 10 
mL 
Mass in 2 
mL 
Final Mass 
 
0 min 0 0 0 0 
5 min 0.36 3.60 0.72 3.60 
Time 
(min) 
Average 
Mass 
𝝈 
10 min 0.94 9.39 1.88 10.11 0 0 0 
n=2 
Recovery 
Area 
Mass in 10 
mL 
Mass in 2 
mL 
Final Mass 5 4.29 0.98 
0 min 0 0 0 0 10 12.27 3.05 
5 min 0.50 4.98 1.00 4.98 
 
10 min 1.34 13.43 2.69 14.43 
 
 
Table A.12 Final drug release and respective standard deviation (𝝈) correspondent to formulation #8P, in SSF 
dissolution media. 
 
 
n=1 
Recovery 
Area 
Mass in 10 
mL 
Mass in 2 
mL 
Final Mass 
 
0 min 0 0 0 0 
5 min 1.66 16.56 3.31 16.56 
Time 
(min) 
Average 
Mass 
𝝈 
10 min 0.83 8.33 1.67 11.64 0 0 0 
n=2 
Recovery 
Area 
Mass in 10 
mL 
Mass in 2 
mL 
Final Mass 5 11.66 6.93 
0 min 0 0 0 0 10 10.56 1.53 
5 min 0.68 6.76 1.35 6.76 
 
10 min 0.81 8.12 1.62 9.47 
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Table A.13 Final drug release and respective standard deviation (𝝈) correspondent to the pure drug substance, in 
SSF dissolution media. 
 
 
 
n=1 
Recovery 
Area 
Mass in 
10 mL 
Mass in 
2 mL 
Final Mass 
0 min 0 0 0 0 
5 min 1.07 10.70 2.14 10.70 
10 min 1.03 10.30 2.06 12.44 
n=2 
Recovery 
Area 
Mass in 
10 mL 
Mass in 
2 mL 
Final Mass 
Time 
(min) 
Average 
Mass 
𝝈 
0 min 0 0 0 0 0 0 0 
5 min 1.13 11.30 2.26 11.30 5 10.40 1.09 
10 min 1.10 10.97 2.19 13.23 10 12.12 1.31 
n=3 
Recovery 
Area 
Mass in 
10 mL 
Mass in 
2 mL 
Final Mass 
0 min 0 0 0 0 
5 min 0.92 9.19 1.84 9.19 
10 min 0.88 8.84 1.77 10.68 
 
 
 
 
Table A.14 Final drug release and respective standard deviation (𝝈) correspondent to the amorphous drug 
substance, in SSF dissolution media. 
 
 
 
n=1 
Recovery 
Area 
Mass in 
10 mL 
Mass in 
2 mL 
Final Mass 
0 min 0 0 0 0 
5 min 1.19 11.88 2.38 11.88 
10 min 2.28 12.80 2.56 15.18 
n=2 
Recovery 
Area 
Mass in 
10 mL 
Mass in 
2 mL 
Final Mass 
Time 
(min) 
Average 
Mass 
𝝈 
0 min 0 0 0 0 0 0 0 
5 min 1.59 15.91 3.18 15.91 5 11.93 3.95 
10 min 1.78 17.75 3.55 20.93 10 16.03 4.53 
n=3 
Recovery 
Area 
Mass in 
10 mL 
Mass in 
2 mL 
Final Mass 
0 min 0 0 0 0 
5 min 0.80 8.01 1.60 8.01 
10 min 1.04 10.38 2.08 11.98 
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Table A.15 Final drug release and respective standard deviation (𝝈) correspondent to the commercial product, in 
SSF dissolution media. 
 
n=1 
Recovery 
Area 
Mass in 10 
mL 
Mass in 2 
mL 
Final 
Mass 
0 min 0 0 0 0 
5 min 0.07 0.73 0.15 0.73 
10 min 0.31 3.08 0.62 3.23 
n=2 
Recovery 
Area 
Mass in 10 
mL 
Mass in 2 
mL 
Final 
Mass 
Time 
(min) 
Average 
Mass 
𝝈 
0 min 0 0 0 0 0 0 0 
5 min 0.12 1.15 0.23 1.15 5 0.80 0.33 
10 min 0.29 2.89 0.58 3.12 10 3.24 0.13 
n=3 
Recovery 
Area 
Mass in 10 
mL 
Mass in 2 
mL 
Final 
Mass 
0 min 0 0 0 0 
5 min 0.05 0.51 0.10 0.51 
10 min 0.33 3.28 0.66 3.38 
 
 
From table A.16 to A.20, the obtained results for the pH shift dissolution method applied are explicit, 
considering the calculations explained before.  
 
Table A.16 Final drug release and respective standard deviation (𝝈) correspondent to the pH shift dissolution 
method approach for formulation #7R. 
 
Time 
(min) 
Recovery 
Area 
Mass in the 
volume vessel 
Mass in 3 mL Final Mass Average 
Mass 
𝝈 
n=1 n=2 n=1 n=2 n=1 n=2 n=1 n=2 
0 0 0 0 0 0 0 0 0 0 0 
5 2.26 2.30 67.78 68.93 6.78 6.89 67.78 68.93 68.35 0.81 
15 1.88 2.11 56.40 63.22 5.64 6.32 63.18 70.12 66.65 4.90 
30 1.77 1.95 53.10 58.38 5.31 5.84 65.52 71.59 68.56 4.29 
45 0.52 0.52 51.67 52.00 1.55 1.56 69.40 71.05 70.23 1.17 
60 0.49 0.53 49.01 53.50 1.47 1.60 68.29 74.11 71.20 4.12 
90 0.46 0.33 46.44 33.15 1.39 0.99 67.19 55.36 61.28 8.36 
120 0.48 0.49 47.93 49.48 1.44 1.48 70.07 72.69 71.38 1.85 
150 0.44 0.48 44.18 47.93 1.33 1.44 67.76 72.63 70.19 3.44 
180 0.40 0.46 39.66 45.73 1.19 1.37 64.57 71.87 68.22 5.16 
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Table A.17 Final drug release and respective standard deviation (𝝈) correspondent to the pH shift dissolution 
method approach for formulation #8C. 
 
Time 
(min) 
Recovery 
Area 
Mass in the 
volume vessel 
Mass in 3 mL Final Mass Average 
Mass 
𝝈 
n=1 n=2 n=1 n=2 n=1 n=2 n=1 n=2 
0 0 0 0 0 0 0 0 0 0 0 
5 0.91 1.61 27.21 48.19 2.72 4.82 27.21 48.19 37.70 14.84 
15 1.21 1.49 36.22 44.59 3.62 4.46 38.94 49.41 44.18 7.40 
30 1.38 1.57 41.25 47.13 4.13 4.71 47.60 56.40 52.00 6.23 
45 0.45 0.48 44.54 48.49 1.34 1.45 55.01 62.48 58.75 5.28 
60 0.45 0.49 45.25 49.10 1.36 1.47 57.06 64.55 60.80 5.30 
90 0.48 0.48 48.41 47.88 1.45 1.44 61.57 64.80 63.18 2.28 
120 0.46 0.45 46.45 44.91 1.39 1.35 61.06 63.26 62.16 1.56 
150 0.43 0.44 43.21 43.55 1.30 1.31 59.22 63.26 61.24 2.85 
180 0.42 0.44 42.32 44.26 1.27 1.33 59.62 65.27 62.45 3.99 
 
 
Table A.18 Final drug release and respective standard deviation (𝝈) correspondent to the pH shift dissolution 
method approach for formulation #7P. 
 
 
Time 
(min) 
Recovery 
Area 
Mass in the 
volume vessel 
Mass in 3 mL Final Mass Average 
Mass 
𝝈 
n=1 n=2 n=1 n=2 n=1 n=2 n=1 n=2 
0 0 0 0 0 0 0 0 0 0 0 
5 1.38 1.60 41.54 48.05 4.15 4.81 41.54 48.05 44.80 4.60 
15 1.69 1.58 50.77 47.26 5.08 4.73 54.93 52.07 53.50 2.02 
30 1.79 1.49 53.59 44.70 5.36 4.47 62.82 54.24 58.53 6.07 
45 0.48 0.44 47.82 44.05 1.43 1.32 62.41 58.06 60.23 3.08 
60 0.50 0.44 49.73 44.31 1.49 1.33 65.76 59.63 62.70 4.33 
90 0.51 0.72 50.74 71.67 1.52 2.15 68.26 88.33 78.29 14.19 
120 0.47 0.43 47.38 43.12 1.42 1.29 66.42 61.92 64.17 3.18 
150 0.48 0.43 47.88 42.84 1.44 1.29 68.34 62.94 65.64 3.82 
180 0.47 0.42 46.65 42.31 1.40 1.27 68.54 63.69 66.12 3.43 
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Table A.19 Final drug release and respective standard deviation (𝝈) correspondent to the pH shift dissolution 
method approach for the commercial product not triturated, i.e., coated and dispersible tablet. 
 
 
Time 
(min) 
Recovery 
Area 
Mass in the 
volume vessel 
Mass in 3 mL Final Mass Average 
Mass 
𝝈 
n=1 n=2 n=1 n=2 n=1 n=2 n=1 n=2 
0 0 0 0 0 0 0 0 0 0 0 
5 0.58 0.72 17.34 21.49 1.73 2.15 17.34 21.49 19.42 2.93 
15 1.91 1.73 57.43 51.91 5.74 5.19 59.16 54.05 56.61 3.61 
30 2.35 2.25 70.39 67.55 7.04 6.76 77.87 74.89 76.38 2.11 
45 0.58 0.60 58.21 59.88 1.75 1.80 72.73 73.98 73.35 0.88 
60 0.62 0.61 61.85 61.18 1.86 1.84 78.11 77.07 77.59 0.74 
90 0.60 0.58 59.65 58.50 1.79 1.75 77.76 76.22 76.99 1.09 
120 0.52 0.55 52.07 54.65 1.56 1.64 71.98 74.13 73.05 1.52 
150 0.53 0.52 52.99 52.24 1.59 1.57 74.46 73.36 73.91 0.78 
180 0.52 0.54 52.04 54.23 1.56 1.63 75.10 76.92 76.01 1.29 
 
 
Table A.20 Final drug release and respective standard deviation (𝝈) correspondent to the pH shift dissolution 
method approach for the commercial product triturated, i.e., powder. 
 
 
Time 
(min) 
Recovery 
Area 
Mass in the 
volume vessel 
Mass in 3 mL Final Mass Average 
Mass 
𝝈 
n=1 n=2 n=1 n=2 n=1 n=2 n=1 n=2 
0 0 0 0 0 0 0 0 0 0 0 
5 2.10 2.43 63.11 72.95 6.31 7.29 63.11 72.95 68.03 6.96 
15 1.97 2.13 59.03 64.01 5.90 6.40 65.34 71.30 68.32 4.22 
30 1.62 1.93 48.58 57.96 4.86 5.80 60.80 71.65 66.23 7.68 
45 0.47 0.48 46.62 47.99 1.40 1.44 63.70 67.48 65.59 2.68 
60 0.49 0.47 49.22 47.45 1.48 1.42 67.69 68.38 68.04 0.49 
90 0.43 0.46 42.69 45.81 1.28 1.37 62.63 68.17 65.40 3.91 
120 0.44 0.45 43.58 45.31 1.31 1.36 64.81 69.04 66.93 2.99 
150 0.42 0.43 41.88 42.78 1.26 1.28 64.42 67.87 66.14 2.44 
180 0.41 0.41 40.95 41.48 1.23 1.24 64.74 67.85 66.29 2.20 
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B. XPS Analysis 
 
 
 
Figure B.1 SEM micrograph correspondent to the physical mixture (blend drug:polymer in the same proportion 
used to produce the formulations, 60:40 % wt.) at a magnification of 1 500x. 
 
 
 
Figure B.2 SEM micrograph correspondent at the model pure drug at a magnification of 1 500x. 
 
